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Abstract 
 
 
Epitope density appears to be a critical factor in pathogens that can elicit effective 
immune responses. All the viruses that have efficacious FDA-approved target vaccines have high 
surface densities of antigens. HIV, on the other hand, has limited number of envelope 
glycoproteins present on individual virions on average, a characteristic with which HIV can 
evade from human immunity. To investigate how immune cells, particularly B cells, recognize 
and differentiate surface antigen density, we aim to build nanoparticles with different densities of 
antigens on the surface. Liposomes are chosen as antigen carriers for their clinical safety and 
engineering versatility. Both ensemble biochemistry assay and single-molecule biophysical 
techniques are developed to determine the spatial density of two model proteins on liposomal 
surface. Our results showed the initial density of protein conjugated on Ni-chelating liposomes 
could be finely controlled but decreased overtime. In comparison, maleimide-liposomes 
performed well in both protein density control and conjugation stability. Through maleimide-
cysteine reaction, we successfully constructed liposomes with varied surface density levels of 
TNF-α peptide, a model self-antigen that is critical in the pathogenesis of rheumatoid arthritis. 
Immunization of mice using liposomes that display TNF-α peptide at high density consistently 
elicited both IgM and class-switched IgG antibodies that are reactive towards self-antigen TNF-α 
protein. In transgenic mice lacking either functional T-cell receptors or MHC II on B cells, the 
liposomal particles elicited similar levels of IgM and IgG responses, implying that this is a T-
independent process.  Addition of CpG or T-cell epitope tetanus toxin peptide improved antibody 
 xiv 
responses elicited by liposomal particles but not by soluble antigen peptide. Furthermore, the Ab 
titer elicited can be increased by 1000-fold upon replacement of liposomes by bacteriophage Qβ 
virus-like particles of similar epitope densities.  Remarkably, this enhancement of Ab titer is 
almost lost entirely in transgenic mice lacking TCR or MHC II, which uncovers T cell help as 
the dominant mechanism behind this enhancement. In conclusion, high epitope density alone can 
trigger antibody class switching in B cells, and the cognate T-cell help recruited by components 
in VLPs can further boost antibody response by promoting affinity maturation. As an exploratory 
work to build on this mechanism of immunogenicity, we attempted next to build HIV VLP using 
the recombinant HIV Gag protein, which is known to contain many well-defined human T cell 
epitopes. If successful, the display of HIV envelope glyproteins on the surface of this VLP at 
high density may afford an attractive lead for HIV vaccine development. HIV Gag protein can 
self-assemble in vitro to HIV virus-like particles, however, the quantitative aspects and in 
particular, the yield of this process are poorly characterized. Our results revealed that purified 
Gag proteins assembled into aggregates as large as micron-sized particles that are visible under 
light microscope. This self-assembly is induced by addition of nucleic acids and interestingly, it 
is reversible with addition of excess nucleic acids. Thus, further engineering of this process is 
required to in order to make it useful for production of HIV VLPs.  In summary, our study 
overall has answered a fundamental question in immunology regarding B-cell activation by 
particulate antigens, offering insights to the process of pathogen recognition. These findings will 
help guide future design of therapeutic vaccines for chronic conditions including cancer and 
Alzheimer’s disease, as well as prophylactic vaccine for infectious agents like HIV.  
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Chapter 1  
Introduction 
 
 
 
1.1. Background 
 
HIV and Its Low Surface Envelope Protein Density 
 
Since human immunodeficiency virus type 1 (HIV-1) was identified as the causative agent 
of acquired immunodeficiency syndrome (AIDS), almost 78 million people have been infected 
with the HIV virus and about 39 million people have died of AIDS1. HIV/AIDS has become the 
biggest burden among infectious diseases all over the world. In last thirty years, a lot of efforts 
have been put into the research of HIV vaccine development, but only until recently, the first 
vaccine candidate to exhibit evidence for protection against infection was reported after RV144 
trial, showing 31.2% vaccine efficacy in a group of 16,395 subjects, yet the extent and mode of 
protection are still under debate2.  
 
HIV has multiple ways to evade the human immune system, including rapid mutation of 
the two glycoproteins that comprise the envelope trimer, gp120 and gp41, and structural features 
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that enables the trimer to hide conserved epitopes from antibodies, such as a shield of host-
derived carbohydrates, conformational masking, steric occlusion and so on3. Besides all the 
features above, HIV also has a very low surface envelope protein density, compared to other 
virions of the similar size such as influenza, measles, papillomavirus and hepatitis B viruses 
(Figure 1.1). For example, influenza type A virus incorporates ~450 trimers per virus particle 
spaced at intervals less than 10 nm4,  while cryo-EM studies revealed that virions of wild-type 
HIV had ~14 envelope trimers per particles, with some clustering of HIV trimers and most 
spikes are separated by distances that far exceed the 15 nm reach of the two Fab arms of an 
IgG5,6.  This low number of envelope trimers on HIV virion surface may be a potential reason 
that human immunity fails to develop neutralizing antibodies specific to HIV virions promptly.  
 
Low Surface Antigen Density May Help HIV Evade Human Immunity 
 
In a review written by Dr. Rolf Zinkernagel in 1996, various virus parameters and their 
capacity to induce T-cell-independent (TI) IgM responses were listed and compared. All viruses 
that induce TI antibodies exhibit highly organized surface antigens, while those lacking a highly 
organized surface structure do not induce TI antibodies7. Although TI antibody responses are 
usually short-lived and mostly IgM, the initial TI B-cell response can lead to a rapid expansion 
of specific B cells without the need of prior Th cell induction, thus greatly enhancing the chance 
for a cognate T-B-cell interaction for a more rapid and rigorous IgG response8. The low number 
of trimers and the large distance between each trimer on the HIV surface can lead to no or little 
TI response, and thus a substantial delay in specific antibody production compared to other 
viruses.  
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Besides the potential lack of TI response, the small number of envelope trimers can also 
attribute to their low binding affinities with specific antibodies. The Fabs region of an IgG 
antibody are linked to the Fc region by a flexible hinge, which typically allows a 10-15 nm 
center-to-center separation between the antigen-binding sites of two Fabs for IgGs9. However, 
the majority of nearest neighbor distances of HIV envelope trimers falls outsides the range of 10-
15 nm, leaving only a minority of HIV envelope trimers available for cross-linking by a bivalent 
antibody5, which limits the ability of the humoral immune response to recognize and neutralize 
the viruses present in body fluids.  
 
Additionally, the low density of envelope trimers on HIV may also be the reason that HIV 
virus have a very low infectivity of less than 0.1% in plasma or culture media10. Envelope 
protein contents have been correlated with the infectivity of the virions. The infectivity of simian 
immunodeficiency virus (SIV) were increased for more than 100 folds when a mutation was 
made to increase the amount of envelope to be incorporated onto the virion11. Clinical studies 
have shown that transmitted founder HIV viruses are enriched for higher envelope protein 
content, enhanced cell-free infectivity, improved dendritic cell interaction, and relative IFN-α 
resistance12.  Although it seems unlikely that HIV evolved the feature of low density of envelope 
protein to limit its infectivity and thus transmission efficiency, low density of envelope protein 
may prevent HIV virion from being cross-linked with neutralizing antibodies and delay the 
induction of a broad spectrum antibody response through lack of TI response, which generate a 
lot of evolutional advantages that overcome the disadvantage of low infectivity. 
 
Surface Antigenic Density and B Cell Response 
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The induction of efficient B cell responses requires two sets of signals: the first is mediated 
by the BCR, while the second is usually provided by T cells. Antigens that stimulate antibody 
production in the absence of MHC class II-restricted T  cell help are classified as T cell-
independent (TI) antigens13. Traditionally, TI responses have been categorized according to 
whether they can be elicited in CBA/N mice, which have an X-linked immunological defect 
caused by deficiency in the kinase Btk14: antigens that do not elicit responses in CBA/N mice are 
designated ‘TI type 2’ (TI-2), whereas those that do elicit antibody responses in the absence of 
Btk are designated ‘TI type 1’ (TI-1). TI-1 antigens provide a second signal via Toll-like 
receptors (TLRs) specific for microbial products such as lipopeptides, lipopolysaccharide (LPS), 
microbial CpG DNA, viral RNA and certain viral coat proteins15; while TI-2 are typically 
multivalent antigens and they are believed to extensively crosslink BCRs and deliver a prolonged 
and persistent signal to the B cell, transmitted via Btk. Typical TI-2 antigens are bacterial 
capsular polysaccharides, such as those found in Streptococcus pneumoniae, Haemophilus 
influenzae type b and Neisseria meningitidis, but TI-2 responses can also develop in response to 
the highly repetitive motifs found in viral capsids16.  
 
Many studies have revealed that in vivo antibody response to viral, bacterial and fungi 
infections consist of both T-dependent and T-independent components, depending on epitopes 
being studies and the infectivity of the organism13. For example, in the response to infection with 
Trypanosoma brucei, a T cell-independent antibody response to the exposed surface glycoprotein 
was observed. In contrast to the response seen after active infection, immunization of mice with 
purified glycoprotein or paraformaldehyde-fixed parasites elicited only a T-dependent response 
to the glycoprotein17. Hepatitis B virus infection is a vigorous TI IgM anti-hepatitis core (HBc) 
antibody production during the early acute stage of infection and a later switch to TD production 
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of IgG anti-hepatitis core antigen18. Similarly, influenza virus can induce specific TI IgG in mice 
lacking CD40 or CD4 T cells, and those mice can recover from influenza infection in a manner 
similar to that of normal mice19. However, whether the TD or TI nature of the response reflects 
the density of the exposed glycoprotein epitopes on the organisms or whether it reflects 
differences in the ability of different organisms to recruit certain cytokines or cells into the 
response, remains to be determined. To study the relationship between surface antigen density 
and TI B cell response, many researchers have conducted remarkable studies using various 
models: early studies showed that the repetitive structure of the polymerized flagellin is able to 
induce B cell response, whereas monomeric flagellin cannot induce B cell response20; 
Haptenated polymers with a minimum number of 12-16 antigenic determinants spaced 
approximately 10nm apart are able to activate B cells in the absence of T cell help21… These 
results showed that B cell responses against highly organized antigens requires none or less T 
cell help than poorly organized or monomeric antigens.  
 
High Surface Density Can Be A Signal of Foreignness for Immune System 
 
Furthermore, it has been proposed that the density of surface antigen may be an important 
marker of foreignness for B cell to recognize. Surfaces of viruses, bacteria, and parasites tend to 
be repetitive, quasi-crystalline in nature, while cell surface molecules almost never form stable 
clusters such as those found on viral surfaces but remain laterally mobile, rendering them less 
able to activate B cells22. In vesicular stomatitis virus glycoprotein (VSV-G) transgenic mice, 
where VSV-G was encoded as a self-antigen, B cells were unresponsive to the soluble VSV-G or 
poorly organized VSV-G but responded promptly to the same antigen presented in the highly 
organized form on inactivated VSV23. Corroborating results were found when tolerant hen egg 
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lysozyme (HEL) -specific B cells were activated by membrane-bound organized form of HEL 
but not the soluble HEL24. A recent study showed that when immunized with virus-like particle 
(VLP) conjugated with self-antigen TNF-	", mice will produce higher titers of TNF-"-specific 
IgG antibodies to those VLPs with high density of TNF-	" rather than low density of TNF-	", 
even though the total amount of TNF-	" was the same25. Collectively, these results suggest that 
B cell can be directly activated by antigens displayed in a highly-repetitive, organized manner. In 
effect, the immune system is largely unable to distinguish between self and foreign proteins 
based on antigenic epitopes but does so based on antigenic organization.  
 
In healthy individuals, immune cells are evolved to mount effective immune response 
against foreign antigens but remain unresponsive to various self-antigens through mechanisms of 
tolerance. Both B cells and T cells developed immune tolerance in both central (bone marrow, 
thymus) and peripheral (spleen, lymph nodes) through various processes including clonal 
deletion, involving apoptosis, receptor editing, anergy and ignorance26,27. Anergy refers to a state 
in which self-reactive B cells exist in the periphery but are quiescent and unresponsive to antigen 
stimulation. Anergic B cells typically have reduced lifespan, altered migration and anatomical 
localization, inability to interact productively with T cells, and downmodulation of surface IgM 
compared to normal mature B cells26. It was found out that as many as 50% of newly produced B 
cells are destined to become anergic, making anergy the primary mechanism by which 
autoreactive B cells are silenced28.  
 
B cell tolerance, particularly B cell anergy, can be overcome experimentally. High density 
display of self-antigen was shown to break B cell tolerance. In a study led by John Schiller, 
multivalent virus-like particle (VLP)- based immunogen could induce autoantibody responses in 
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transgenic mice that express soluble form of hen egg lysozyme tolerated by B cells through 
anergy. Adoptive transfer model study showed the immunization with VLP, but not trivalent 
form of hen egg lysozyme reversed B cell anergy in vivo29. However, the mechanism under 
which highly dense, multivalent antigens can activate B cells still remains unclear. One theory is 
that extensive crosslinking of BCR by high density of antigen display induces the association of 
the BCR with detergent-insoluble lipid rafts that are associated with long-term stable activation 
of tyrosine phosphorylation30,31. Still, the role of T-cell help or Toll-like receptor signal is yet to 
be understood.  
 
Our design of engineered particles aims to answer several fundamental immunology 
questions: Does human B cell directly recognize highly-repetitive antigen displayed on 
pathogens? Is the recognition process dependent on help from T cells or other cells? What are the 
recognition mechanism and activation pathways involved? The answers to these questions will 
not only expand our knowledge of human immunity, but also give indications to future vaccine 
design. Current vaccine development mainly focuses on the arm of TD B cell response, due to 
the common belief that TI antigens will not elicit germinal center (GC) formation and memory B 
cell differentiation. Recent studies have revealed that some TI antigens are capable to induce 
long-lived TI memory B cells that originate from B-1b cells, which provided rapid IgM specific 
antibody protection upon the second challenge32, and two independent studies have demonstrated 
that the prototypic TI antigen NP-Ficoll induces GCs in nude mice33,34. More importantly, TI 
antigens may serve as a rapid stimulus to specific B cells and induce their clonal expansion, thus 
leading to an easier recognition of cognate T cells and a stronger TD response7. Our study may 
help to reveal the surface antigen density that is optimal for T-independent B cell activation, 
which would greatly facilitate future vaccine design strategy. 
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1.2. Significance 
 
Understanding of Surface Density Factor in Immunology 
  
Our study aims to answer several fundamental immunology questions: Does B cell directly 
recognize the density of antigens as a signal? Does B cell have different density threshold 
requirement for self-antigens and foreign antigens? What is the recognition mechanism and 
activation pathways? Is this activation process independent on T cells or other cells? The 
answers to these questions will not only expand our current knowledge of human immunity, but 
also give indications to future vaccine design, especially to pathogens with no existing effective 
vaccine like HIV.  
 
One approach for HIV vaccine is to develop high-density virus-like display of HIV antigen 
to induce broadly neutralizing antibody. A study showed HIV virus-like particles with increased 
density of envelope glycoprotein (Env) have superior activation of Env-specific B cells35. 
Nanoparticle presentation of HIV Env on carriers like liposomes or ferritin particles have also 
been explored: high density of Env display more efficiently activates Env-specific B cells ex vivo 
and enhances the generation of germinal center B cells in vivo36,37. These studies utilizing high 
density display of HIV antigens represent a promising lead towards development of an effective 
HIV vaccine.  
 
Another implication in understanding surface density factor is to employ high-density 
display of self-antigen to break B-cell tolerance and elicit auto-reactive antibodies. Monoclonal 
antibody specific for host proteins have proven to be highly effective in the treatment of 
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autoimmune diseases, such as rheumatoid arthritis and Crohn’s disease. More antibody drugs 
against self-antigens are under development for the treatment of many chronic conditions 
including cancer, hypertension and Alzheimer’s disease38,39. 
 
Clinical Use of Therapeutic Antibody Against Self-Antigen in Autoimmune Diseases 
 
A number of antibody drugs specific for pro-inflammatory cytokine tumor necrosis factor 
alpha (TNF-α) have been developed and achieved success in both clinical use and the market 
place. The mechanism of  action is that anti-TNF-α monoclonal antibody drugs can specifically 
neutralize TNF-α in patients with active rheumatoid arthritis, psoriatic arthritis and ankylosing 
spondylitis to relieve symptoms caused by elevated levels of TNF-α 40–42.  
 
Among these antibody drugs, Adalimumab is the first fully human, high-affinity, 
recombinant immunoglobulin G1 anti- TNF-α monoclonal antibody for the treatment of 
rheumatoid arthritis43. For patients who do not respond to traditional disease-modifying 
antirheumatic drugs (DMARD) (e.g., methotrexate, leflunomide), 32 percent of patients will 
experience a major clinical response when adalimumab is substituted44. When combined with 
methotrexate, the remission rates reaches to 43 percent and response rate nearly doubles (62 
percent)45. Adalimumab requires subcutaneous self-injection every other week; more than 10% 
of patients have reported inconvenient or unable to self-inject due to disease condition46. The 
cost of Adalimumab is approximately $1662 per month, more than 20 folds of the cost of 
methotrexate ($13 to $85 per month)47, making it the top per-person drug spending in 201648. 
The high cost and frequent administration limited the use of adalimumab in resource-limited 
communities and developing countries.  
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Given the success of passive vaccination with therapeutic monoclonal antibodies, a better 
strategy to actively induce the same therapeutic antibodies in situ is envisioned. In mouse 
models, active vaccination against TNF-α elicited effective production of anti- TNF-α 
neutralizing antibodies, sufficient in controlling the symptoms of arthritis49. One study led by 
John Schiller using papillomavirus VLPs with TNF-α peptides conjugated to the surface for 
mouse immunization revealed that VLP attached TNF-α induced 1000 folds higher autoantibody 
production compared to soluble TNF-α. Vaccination with conjugated particles also inhibited 
development of type II collagen-induced arthritis in mouse model50.  
 
Potential of Therapeutic Vaccines Against Self-Antigens in Chronic Diseases 
 
Beyond rheumatoid arthritis, therapeutic vaccines against self-antigens are applicable to 
many other chronic diseases. Today, many therapeutic vaccines are under development for 
conditions including cancer, Alzheimer’s disease, diabetes, hypertension and obesity. One 
vaccine candidate for prostate cancer, D17DT, consisting of the GnRH (gonadotrophin releasing 
hormone) was shown to elicit significant anti-GnRH antibody titer in volunteers and almost half 
of patients vaccinated achieved castrate level of testosterone, proving great potential in 
controlling prostate cancer51. Similarly, G17DT, a vaccine candidate for pancreatic cancer, is 
also acting towards a self-antigen gastrin (growth factor for pancreatic cancer). In phase II trials 
of G17DT, 20 of 30 patients produced an antibody response; Antibody responders demonstrate 
significantly greater survival than antibody non-responders52. For treatment of hypertension, a 
novel vaccine based on angiotensin II- derived peptide conjugated VLP Q# demonstrated high 
efficacy in reducing systolic blood pressure in spontaneously hypertensive rats. The followed 
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clinical trial in human showed good tolerance and 100% response rate in production of anti-
angiotensin antibody53. 
 
The Alzheimer’s disease vaccines also rely on self-antigens. Alzheimer’s disease is a 
chronic condition of neurodegeneration allegedly caused by deposition of amyloid β-peptide 
(Aβ) in plaques in brain tissue54. The goal of the vaccine is to immunize patients against Aβ so 
that the accumulation of plaque in brain will stop and cognitive functions will be restored. 
Vaccination towards Aβ-peptide in mouse disease model resulted in reduced plaque mass and 
improved their mental performance55,56. Despite of good tolerance and no side effect in 
vaccination to mice, anti-Aβ vaccines caused symptoms of acute meningoencephalitis in 6% of 
vaccinated patients in phase I trial57. Nevertheless, a phase II study revealed a substantial delay 
of cognitive decline in patients that produced anti-Aβ antibodies58. Besides chronic diseases like 
cancer and hypertension, this vaccination strategy has also applied to contraception use. A 
vaccine toward human chorionic gonadotropin (hCG) was developed and put to clinical trials: a 
heterospecies dimer of the beta subunit of human chorionic gonadotropin (hCG) associated 
noncovalently with the alpha subunit of ovine luteinizing hormone and conjugated to tetanus and 
diphtheria toxoids as carriers effectively elicited anti-hCG antibody and only 1 pregnancy was 
recorded for vaccinated fertile women over 1224 cycles59,60.  
 
Overall, understanding of high-density display in breaking B cell tolerance will guide the 
development of therapeutic vaccines towards various self-antigen targets. Our study aims to 
reveal the role of antigen density in B cell activation quantitatively through construction of a 
novel nanoparticle platform with controlled densities of antigens. The results will further our 
current understandings in antigen surface density and offer insights to our future vaccine design. 
 12 
 
1.3. Hypothesis and Specific Aims 
 
Specific Aim 1:  
Construction of Nanoparticles with Tailored Densities of Surface Antigens  
 
We hypothesize antigen density is a key factor in eliciting B cell response, and it has 
different requirements of density threshold for B cells to activate upon self-antigens or foreign 
antigens. As illustrated in Figure 1.2, the density threshold for foreign antigens is low, as many 
in soluble monomeric forms still activates B cells effectively, while self-antigens under their 
density threshold will be tolerated by B cells. Once self-antigen density exceeds the threshold, B-
cell tolerance breaks and B cells are activated. When both antigens have very high density, B cell 
activation may be lowered and B cell tolerance may be restored61.  
 
To validate this hypothesis, we aim to construct nanoparticles with tailored densities of 
antigens on the surface. HIV VLP is the first particle platform we attempt to use. Previous 
studies showed HIV matrix protein Gag assembled into virus-like particles in vitro62–64. Without 
the using of cells, these VLPs will not carry any additional proteins other than target antigens65. 
An additional benefit of HIV VLP is that it contains the Gag protein as potent T-cell epitopes, 
soliciting T-cell help for B cell activation. By fusion of HIV Gag protein with target antigens, we 
can build VLP with target antigens presented on the surface with a fixed orientation. We hope to 
control the surface density of antigens on VLPs by manipulating the ratio of Gag-fusion protein 
and unmodified Gag protein during their assembly in vitro. 
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A second choice of nanoparticle platform is liposome. Liposomes are well documented 
drug delivery systems with a safe record of clinical applications66,67. As antigen carrier, 
liposomes have multiple advantages including safety, low immunogenicity, versatility in 
engineering and production. Here, we aim to construct liposomes, similar to HIV VLP in size 
and shape, with various densities of surface antigens. To conjugate target antigens on liposomes, 
we plan to explore different conjugation methods reported by literature. For example, Ni-NTA- 
his-tag binding was used in a recent study conjugating HIV Env protein on the surface of 
liposomes37; Chemical conjugation such as maleimide reaction has also been used in peptide 
conjugation on liposomes68.  
 
 
Specific Aim 2:  
Characterization of Engineered Nanoparticles and Their Surface Antigen Densities  
 
Following the construction of nanoparticles with antigens on the surface, we aim to 
characterize the nanoparticles in terms of size, surface charge, homogeneity in size and antigen 
densities. Among these parameters, the surface density of antigens is the key factor to be 
determined. We have designed two methods for antigen density quantitation: bulk biochemical 
assay and single-molecule fluorescence assay. The bulk assay aims to use the Stewart Assay to 
quantitate lipid amount and use SDS-PAGE (SDS- polyacrylamide gel electrophoresis) to 
quantitate protein amount. The molar amounts of both combined gives rise to the average antigen 
density on the nanoparticles.   
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To determine the heterogeneity of peptide density among individual nanoparticle, we resort 
to fluorescence labeling of peptide on the surface of nanoparticles. By labeling all the peptide 
molecules specifically on the particle surface and observing under fluorescence microscopy and 
optical tweezers, we are capable to quantitate the number of molecules on individual particles. 
Through this method, the heterogeneity of peptide densities on nanoparticles can be observed 
and evaluated. We aim to achieve a homogeneous distribution of antigen density among 
nanoparticles, so particles with low antigen density do not contain some high-density particles 
that influence the immune response outcomes.  
 
Moreover, the stability of antigen conjugation on nanoparticles are critical to our study. 
We aim to construct engineered nanoparticles with stable conjugation with antigens in the 
presence of serum. Upon inoculation in mice subcutaneously or intravenously, nanoparticles are 
expected to transit through blood vessel, tissues, lymph vessels and lymph nodes. Nanoparticles 
require a stable conjugation with antigens so that the antigen density level does not change 
drastically before entering lymph nodes and exposure to naïve B cells. For this purpose, we plan 
to evaluate the kinetics of antigen association/ dissociation on liposomal surface by quantitating 
the number of antigens on individual liposomes during days of incubation in serum.  
 
Besides antigen density, characterization of nanoparticles in size, surface charge, and size 
homogeneity will be carried out by dynamic light scattering and electron microscopy. The 
physical stability of nanoparticles with antigens in serum will be tested to ensure no aggregation 
or precipitation occurs upon interaction with serum proteins.   
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Specific Aim 3:  
Study of B cell Activation by Engineered Nanoparticles In vivo and In vitro 
 
To determine the effects of surface antigen density, we aim to use nanoparticles with self-
antigens of different densities for study of B cell activation (Figure. 1.3). As described 
previously, we hypothesize that B cell activation requires a higher threshold of antigen density 
for self-antigen compared to foreign antigens. Thereby, we will use engineered nanoparticles 
with different levels of self-antigen density to directly immunize wild-type mice and study if B 
cell tolerance of self-antigen can break. Through ELISA and flow cytometry, we can estimate the 
level of specific autoantibody production and the amount of specifically activated B cells in 
mice. Furthermore, we are interested in the role of T cells and Toll-like receptors (TLR) in B-cell 
recognition of surface antigen density: addition of T-cell epitopes and TLR ligands to engineered 
nanoparticles for mice immunization can show the effects of T-cell or TLR help for antigen 
density recognition. Moreover, we aim to use transgenic micein v lacking T-cell receptors and 
MHC class II for immunization of engineered nanoparticles to determine the role of T-cell help 
in breaking B-cell tolerance.   
 
In addition to in vivo study, we aim to study B cell activation in vitro as well. As the 
number of specific B cells for one antigen is very low, use of BCR transgenic mice recognizing 
one specific antigen is necessary to obtain large amount of specific B cells. We plan to use HEL- 
BCR specific mice to isolate HEL-specific B cells and study the activation of B cells in vitro 
upon stimulation with nanoparticles of different antigen densities. B cells surface activation 
markers, cytokine production, antibody production and life span will be evaluated as indicators 
of activation and compared between nanoparticles with different antigen densities.   
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1.4. Figures 
 
 
 
 
 
 
Figure 1.1. Comparison of protein densities on virion particle.  
 
(a) HIV-1. (b) Influenza virus. (c) Hepatitis B virus. (d) Yellow fever virus. (e) Measles virus. (f) 
Human adenovirus. (g) Human papillomavirus. (h) Rotavirus. (i) Poliovirus. (j) Hepatitis A 
virus. Models for a-e, g, and h are from cryoelectron microscopy, and models for f, i, and j are 
from crystal structures. Whereas a-e and j are enveloped viruses, f-i are considered as 
nonenveloped viruses. All these viruses have licensed vaccines available except HIV-1.69-78  
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Figure 1.2. Hypothetical model of B cell responses to foreign-epitope and self-epitope 
densities.  
 
For one particular antigen, the epitope density serves as a direct signal to B cells. Only when the 
epitope density is higher than a threshold of responsiveness, will B cells start to be activated. 
This threshold of density is higher for self-epitope than for foreign-epitope.  
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Figure 1.3. Schematic figure of experimental design.  
 
High- or low-density level of self-antigen on nanoparticles (antigen amount in total is controlled) 
are inoculated to mice for study of B cell activation in vivo. Antibody production and activated B 
cell quantitation will determine if B-cell tolerance towards specific self-antigen has been broken.   
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Chapter 2 
 
Construction and Characterization of Liposomes Conjugated 
with Proteins for Controlled Density of Surface Epitopes 
 
 
 
2.1. Abstract 
 
Liposomes have been widely used as antigen carriers due to its safety and flexibility. 
However, one key question remained to be answered is how to stably conjugate antigens on 
liposomes and quantitate the surface antigen density. Ni-chelating liposomes have been widely 
used as protein carriers in experimental studies of vaccine delivery, owing to the convenience 
and versatility of this conjugation chemistry. However, the epitope number per particle as well as 
the stability of protein conjugation on liposomes remain far less characterized. Here we have 
developed quantitative methods to measure the average spatial density of proteins on liposomes 
using both ensemble and single-molecule techniques and demonstrated their utility using 
liposomes conjugated with native proteins of two different sizes. These studies revealed that the 
initial density of protein conjugation on Ni-chelating liposomes can be finely controlled, but the 
density can decrease over time upon dilution due to the noncovalent nature of Ni-chelation 
chemistry. In comparison, peptide conjugated on liposomes through maleimide-cysteine 
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conjugation is much more stable over time. Our study suggests maleimide covalent conjugation 
is a better strategy to precisely regulate the epitope density on liposomes for B-cell antigen 
delivery.  
 
2.2. Introduction 
 
Vaccination is a concept that can be broadly applied to the prevention and treatment of 
human diseases, including but not limited to infectious diseases, cancer and neurodegenerative 
diseases.  Currently, there are more than 90 vaccine products that are licensed for immunization 
and distribution in the US.  The mechanisms of protection in the majority of these licensed 
vaccines are correlated with antibodies1. As a result, how to optimally activate antigen-specific B 
cells for the production of memory B cells is likely to be the key to the success of these vaccines. 
 
There are extensive and well controlled studies in the literature that document the impact 
of epitope density on B-cell responses.  Quantitative differences in epitope density can easily 
produce quantitative or qualitative differences in antibody responses in mouse models of 
immunization 2-5. Indeed, the variation of the spatial density of a protein on a particulate antigen, 
e.g., vaccine candidate, has a direct impact on the antibody response in animals 6,7.  These studies 
revealed that the spatial density of epitopes on particulate antigens is a critical feature that one 
needs to consider for the delivery of B-cell based vaccines.  However, the application of this 
fundamental principle to vaccine delivery remains incompletely developed for two reasons: (1) a 
robust antigen-delivery system is yet to be developed that allows the delivery of antigens, 
especially protein antigens with well-defined spatial densities, and (2) the techniques that are 
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necessary to precisely quantitate the spatial density of epitopes on particulate antigens remain 
lagging behind.  
 
Varieties of nanomaterials have been developed over the past decade for the experimental 
delivery of various immunogens 8,9.  A simple and yet versatile approach is the protein-
conjugated liposomes.  Liposomes are well documented drug delivery systems with a safe record 
of clinical applications 10,11.  Liposome and liposome-derived nanovesicles have become 
important platforms for carrying antigens and immune-stimulatory molecules for vaccine 
development.12  A variety of different parameters including the lipid composition, size, charge, 
and antigen conjugation can be manipulated for various applications.13  At least two lipid-related 
vaccine products have been approved: Inflexal V14 and Epaxal15, targeting influenza and 
hepatitis A respectively, and more liposome-based vaccines are at different stages of clinical 
trials.  
 
A potential advantage of liposome for vaccine delivery is that a purified protein can be 
attached to the particle surface through chemical conjugation, during which the density of the 
protein averaged over a single particle may be controlled.  This strategy, if it works, may allow a 
fine control over the spatial density of epitopes per particle to optimize the B-cell antibody 
response.  For anchoring epitope of interests on the surface of liposomes, a variety of 
conjugation methods have been developed16. Among them, Ni-NTA-his-tag conjugation has 
been a widely-accepted choice due to the convenience of its operation. Chelator-lipids were first 
synthesized and characterized for immobilization of engineered proteins at self-assembled lipid 
interface in 199417. Since then, many groups have used liposomes containing metal-ion-chelating 
lipid to attach histidine-tagged protein of interest, which led to an elevated level of immune 
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response compared to traditional forms of antigen.18-21  However, the spatial density of the 
proteins attached on these liposomes was often not reported in these studies.  
 
In this paper, we explore the feasibility to fine control the surface density of epitopes 
attached to unilamellar liposomes and develop quantitative methods to characterize the spatial 
density of epitopes averaged over a single particle.  It is worth noting that proteins attached onto 
the outer surface of liposomes, either covalently or non-covalently, may still be capable of two-
dimensional diffusion on the liposome surface, which may allow formation of protein clusters 
with high local spatial density.  Whether this phenomenon may occur during B-cell recognition 
of the particulate antigens is a subject of future research.  Specifically, herein, the term ‘spatial 
density’ is referred to as the spatial density of proteins that is averaged over a single particle.  
Our results revealed that the initial density of proteins conjugated on liposomes via Ni-chelation 
chemistry can be fine controlled, but the density will decay with time upon dilution.  In contrast, 
the epitope density is more stable upon dilution for epitopes conjugated onto the liposome 
surface via thiol-maleimide chemistry.  These results support thiol-maleimide reaction instead of 
Ni-chelation chemistry for conjugation of B-cell epitopes onto liposomes and also suggest a 
strategy to regulate the average spatial density of proteins on liposomes for optimization of 
antibody responses.   
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2.3. Materials and Methods 
 
Preparation of Ni-Chelating Liposomes 
 
All liposomes used in this study were prepared using oil-in-water microemulsion precursor 
followed by membrane extrusion as originally described in literature.22-24  Two different lipids at 
designated molar ratios were used in the synthesis of liposomes: DMPC (1,2-dimyristoyl-sn-
glycero-3-phosphocholine) and Ni-NTA-DGS (1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-
carboxypentyl) iminodiacetic acid) succinyl] (nickel salt)) (Avanti Lipids).  Briefly, various 
amount of Ni-NTA-DGS lipid was added into 5 mg DMPC in a round-bottom bottle to reach the 
indicated molar percentage for the Ni-NTA-DGS lipids.  The lipid mixture in chloroform was 
then vacuum desiccated to allow thin film formation at the bottom of the bottle. One mL PBS 
buffer was then added to the bottle to hydrate the lipid film through gentle rocking at 37°C 
overnight.  The next morning, the content was retrieved and extruded through polycarbonate 
membrane of 1000 nm and 100 nm sequentially, each for ten times.  The resulting liposomes 
were then stored at 4°C for all experiments. 
 
Preparation of TNF-α Peptide Conjugated Liposomes via Maleimide-Thiol Addition 
and Alexa-594 Fluorophore Labeling 
 
Liposomes containing maleimide functionalized lipids were prepared using the same 
extrusion method as described above for Ni-chelating liposomes with minor modifications. 
Briefly, DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine), cholesterol, and DSPE-PEG2000-
maleimide (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- [maleimide (polyethylene 
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glycol)-2000]) (Avanti lipids) were included at a molar ratio of 5:3:2 (total lipid amount in moles 
was kept the same as that of Ni-chelating liposomes).  To avoid maleimide hydrolysis during 
lipid film hydration, we adopted vigorous vortex instead of overnight incubation. After the lipid 
film was hydrated in HEPES buffer (100 mM HEPES, 150 mM NaCl, pH 6.9 at 20°C), the lipid 
film resuspension was extruded using polycarbonate membrane with pore sizes of 1000 nm and 
100 nm sequentially for ten times each. Synthesized liposomes were incubated with TNF-α 
peptide (CSSQNSSDKPVAHVVANHQVE, 95% purity, Biomatik Scientific) at molar ratio of 
maleimide to peptide as 3:1. After overnight incubation at room temperature, the liposome 
peptide mixture was applied to Sepharose CL-4B gel filtration column to separate TNF-α 
conjugated liposomes from unconjugated free peptide.  For labeling of Alexa-594 fluorophore 
through free amines, the pH of the peptide conjugated liposomes was first adjusted using one 
tenth volume of 1 M sodium bicarbonate solution.  A stock solution of Alexa Fluor ® 594 
succinimidyl ester (Invitrogen CAT#A37572) was then added to reach a molar ratio of 600:1 
between the fluorophore and the liposome.  The mixture was incubated in dark at 20°C for 15 
min, and the reaction was then quenched by addition of 1 M Tris pH 7.0 to reach a molar ratio of 
500:1 between Tris and the fluorophore.  The labeled liposomes were then passed through 100 
kD molecular weight cut off membrane (Sartorious) at 15 kg for three times to remove free 
fluorophores and stored at 4ºC. 
 
Purification of Hexahistidine-Tagged Proteins 
 
We have used two recombinant proteins of different sizes in this study: the B1 domain of 
streptococcal protein G and the monomeric teal fluorescent protein (mTFP)25.  The B1 domain of 
protein G has a molecular weight of 7.7 kD while the mTFP has a molecular weight of 28 kD, 
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which provides a reasonable size difference for testing conjugation onto liposomes.  Both 
proteins carry a hexahistidine tag at the C-terminus of the respective proteins for attachment onto 
liposomes through Ni-NTA coordination chemistry.  Both proteins were house expressed in E. 
coli BL21(DE3) pLysS strain and purified to greater than 95% purity using nickel-nitrilotriacetic 
acid (Ni-NTA) agarose technology, as judged by intensity comparisons on an acrylamide gel 
loaded with different amounts of final purified proteins.  The native B1 domain of protein G does 
not carry any cysteine residues26.  To site-specifically label a single Alexa-594 fluorophore onto 
the protein for single-molecule studies, we have engineered a single cysteine at position 2, after 
the N-terminal methionine.  We have developed a protocol to label the single cysteine on the B1 
domain with high efficiency.  Briefly, the purified B1 domain was treated with fivefold molar 
excess of TCEP at 4°C for 18 hours.  The excess TCEP was removed by passing the protein 
through a desalting column.  The Alexa-594 maleimide (ThermoFisher) freshly dissolved in 
water was then added to the protein at a tenfold molar excess.  The crosslinking reaction was 
incubated at 20°C for 8 hours.  The reaction was stopped by adding 2-mercaptoethanol to a final 
concentration of 20 mM.  After additional 30 min incubation at 20°C, the labeled protein was 
extensively dialyzed at 4°C using a 3kD molecular weight cut-off membrane against the storage 
buffer containing 50 mM HEPES, 150 mM NaCl pH 7.0 at 22°C in order to remove excess dye 
molecules.  The concentration of the labeled protein was measured by absorbance at 280 nm 
(corrected for dye absorbance at this wavelength) using an extinction coefficient of 9530 M-1cm-
1, and the concentration of the conjugated Alexa-594 was quantified simultaneously by 
absorbance at 590 nm with an extinction coefficient of 9.00 × 104 M-1cm-1.  The efficiency of 
dye labeling was thus calculated to be 96%.  The status of single fluorophore labeling was also 
confirmed by positive ion electrospray mass spectrometry.  This fluorescently labeled B1 domain 
of the streptococcal protein G is referred as rPG throughout this manuscript. 
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Attachment of Proteins to Liposomes and Size Exclusion Chromatography 
 
For attachment of purified proteins onto liposome surface, the purified proteins were 
incubated with synthesized liposomes at 37°C for 1 hour at the indicated molar ratio between the 
proteins and the Ni-NTA group, which is sufficient to reach equilibrium as indicated by a 
comparison with the result from an overnight incubation at the same temperature.  The mixture at 
400 µl volume was then directly applied to the top of a 10-ml Sepharose CL-4B (GE Life 
Sciences) gel filtration column that was already equilibrated in PBS in order to remove excess 
free proteins not bound to liposomes.  The column was run by gravity at 4ºC and again PBS was 
used as the elution buffer.  20 fractions were collected after the sample application and each 
fraction contained 0.5 ml eluate.  To identify fractions containing liposomes, dynamic light 
scattering measurement was conducted for samples from each fraction and the fractions with 
most of the liposomes were pooled and further stored at 4ºC. For each coupling of proteins to 
liposomes reported in this work, the coupling efficiencies of proteins were calculated as the ratio 
between the amount of proteins on liposomes after the size-exclusion column and the initial input 
protein and reported as percentages in Table 2.2. The yield of lipid recovery was also calculated 
as the ratio between the amount of lipids present in liposomes after the size-exclusion column 
and the initial input lipids and reported as percentages in Table 2.2.  
 
Stewart Assay to Measure Lipid Content   
 
We have used the established Stewart assay27 to determine the phospholipid content in the 
purified liposomes, based on which the molarity of the liposomes can be further estimated.  It is 
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worth noting, however, that under Steward assay conditions, Ni-NTA-DGS alone can also give 
rise to non-negligible absorbance at 470 nm that is in linear proportion to the molarity of this 
specific lipid.  Thus, throughout our studies, the phospholipid content measured has been 
corrected based on the percentage of Ni-NTA-DGS in the liposome sample, although this 
correction was minor for most cases.  Purified liposomes bound with fluorescence labelled B1 
domain of the streptococcal protein G or mTFP were both examined using Stewart assay for 
phospholipid quantitation.  Briefly, 100	µL liposome samples were added to 1mL chloroform in 
a clean glass tube, and then 1mL ferrothiocynate solution containing 0.1 M ferric chloride 
hexahydrate and 0.4 M ammonium thiocyanate was added.  The mixture was vigorously 
vortexed for 1 min and further kept at 22ºC in the dark for at least one hour or until its full 
separation into two layers.  The lower aqueous layer was then taken for absorption measurement 
at 470 nm.  The phospholipid content was then calculated based on the comparison with a 
standard curve of DMPC lipids measured under identical conditions.   
 
Estimation of Liposome Molarity Based on Geometric Considerations 
 
To further estimate the molarity of the liposome based on the phospholipid content, we 
used geometric considerations of liposomes.  Briefly, we calculated the number of lipid 
molecules N per liposome using the following equation: 
& = ()*+,-.-/)*+,-01.-23   (1) 
Where D is the diameter of the liposome, h is the thickness of the bilayer, and a is the area 
of the lipid molecule head group.  In our calculation for liposomes prepared using DMPC as the 
major lipids, the bilayer thickness h was taken as 4.6 nm based on previous experimental 
measurement on DMPC bilayers28.  The area of DMPC lipid head group was taken as 0.657 nm2 
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based on X-ray scattering measurement on DMPC lipid vesicles29.  The average diameters of the 
liposomes were measured using dynamic light scattering for each liposomal sample using 
Malvern Zetasizer Nano ZS at 20ºC.  The molarity of the liposomes was then calculated based on 
the measured phospholipid content. 
 
Fluorescence Plate Reader to Measure rPG Content in Liposomes 
 
To measure the rPG protein content in the purified liposome samples, we employed 
fluorescence plate reader (Synergy HT, Biotek).  Briefly, the fluorescence of Alexa-594 was 
recorded using an excitation filter of 590 nm with 20 nm bandwidth, and an emission filter of 
645 nm with 40 nm bandwidth.  Comparison with a standard curve prepared and measured using 
known quantities of corresponding rPG free in PBS solution (0 to 3 ng/µL) yields an estimate of 
protein content in liposome samples.  The corresponding liposome samples without proteins 
contributed negligibly to the fluorescence reading at the above settings.  
 
Epifluorescence Imaging of Liposome Samples 
 
To use single-molecule fluorescence to quantitate the spatial density of rPG on individual 
liposomes, we have employed epifluorescence imaging approach.  Liposome samples after gel 
filtration was diluted 1000 folds and immediately applied onto poly-L-lysine coated coverslips 
for epifluorescence imaging under an IX71 Olympus Advanced Research Fluorescence 
microscope.  Alexa-594 was excited using a 592 nm fiber laser and its emission monitored using 
a 630 nm filter with 40 nm bandwidth.  To record fluorescence with single-molecule sensitivity, 
a laser power of 100 mW, EM gain of 100 and an exposure time of 20 ms were used throughout 
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so that the recorded fluorescence intensity can be directly compared across experiments. All the 
imaging experiments were conducted at 20ºC.  The irradiance of the incident laser on the sample 
was estimated to be 87 mW/cm2 or less, and the heating of the sample by laser irradiation was 
negligible under these conditions. 
 
Inductively Coupled Plasma- Optical Emission Spectrometry (ICP-OES) 
 
We have used ICP-OES (Optima 2000 DV, Perkin-Elmer) to quantitatively measure the 
amount of nickel ions in mTFP-conjugated liposomes collected through a gel filtration column.  
The atomic emission of Ni was detected at both wavelengths of 221 nm and 231 nm.  To 
quantitate the amount of Ni in the liposome samples, a series of reference Ni samples from 100 
ppb to 1000 ppb were prepared and standard curves were constructed.  The final concentration of 
Ni in each sample was determined based on the standard curve and the average values from both 
221 and 231 nm wavelengths was used as the final concentration of the Ni.  Throughout our 
studies, reference Yttrium samples served as internal controls for the instrument by measuring 
their emissions at 371nm.  
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2.4. Results and Discussion 
 
Characterization of the Spatial Density of rPG on Liposomal Surface 
 
To facilitate the quantitation of the spatial density of proteins conjugated onto liposomes, 
we have chosen to use a fluorescent labeled protein, rPG, for attachment onto liposomes via the 
Ni-NTA coordination chemistry.  The site-specific labeling of Alexa-594 fluorophore on this 
protein allows us to quantitate the spatial density of protein attached on liposomes using both 
ensemble and single-molecule fluorescence approaches.  We prepared liposomes by the lipid thin 
film hydration method, followed by membrane extrusion.22-24  For conjugation of proteins onto 
liposome surface, a minor percentage of Ni-NTA-DGS lipid was doped into DMPC during 
liposome preparation.  Extrusion through polycarbonate membrane of 100 nm pore size allowed 
liposome formation with a relatively uniform size.  As shown in Table 2.1A, these synthesized 
Ni-chelating liposomes had an average diameter of 97 ± 1 nm (mean ± standard error) with a 
mean polydispersity index of 0.04 ± 0.02 (mean ± standard error).  The average diameter of these 
liposomes does not change significantly with the increase in the molar percentage of Ni-NTA-
DGS lipids in the range of 0-20% that we have investigated.  
 
To quantitate the spatial density of rPG on liposomes, we started out by focusing on 
liposomes that carried 1% of Ni-NTA-DGS.  After liposome synthesis, a designated amount of 
rPG was incubated with liposomes for 1 hour at 37ºC, followed by purification through gel 
filtration.  This experiment was then repeated using the same amount of liposomes (0.44 µmol 
DMPC) but with increasing concentrations of rPG.  As shown in Table 2.1B, these liposomes 
after rPG association had a measurable increase in their diameters compared to that of the 
 36 
 
liposome alone before rPG binding, consistent with protein binding on the surface of the 
liposomes. To determine the average number of rPG molecules per liposome, we first used 
fluorescent plate reader to measure the fluorescence intensity from the purified liposome 
samples.  Comparison with a standard curve that was constructed using free rPG protein at 
various concentrations in PBS buffer under the same instrument conditions (Fig. 2.5a) allowed 
us to estimate the concentration of rPG in liposome samples.  Control experiments showed that 
incubation of liposomes with rPG did not cause any change in the fluorescence signal for Alexa-
594, suggesting that the quantum yield of Alexa-594 was not significantly perturbed by rPG 
attachment onto liposomes.  Based on the molarity of liposomes calculated using Eq. 1, we can 
thus calculate the average number of rPG molecules per liposome.  This result is shown in Fig. 
2.1a.  As the quantity of rPG increased from 2.5 to 80 µg, the average number of rPG per 
liposome also increased gradually and showed a trend to reaching a plateau, resembling a typical 
binding isotherm.  It is worth noting that at 80 µg rPG, the molar ratio between Ni and rPG is 1: 
1.6, suggesting that the trend of approaching plateau is a result of saturation of all the available 
Ni-NTA binding sites on liposomes, instead of surface crowding, i.e., saturation as a result of the 
crowding of proteins on liposome surface.   
 
To provide further proof for this point, we have thus compared liposomes containing 1%, 
3% and 5% Ni-NTA-DGS (all in molar percentage) for their protein surface densities, as shown 
in Fig. 2.1b.  These liposomes were prepared by incubating the same moles of liposomes (0.44 
µmol DMPC for liposomes with 1% Ni-NTA-DGS) with 30 µg rPG, followed by gel filtration.  
The average number of rPG molecules per liposome increased in a linear fashion with the 
percentage of Ni-NTA-DGS in the liposomes, as indicated by the solid line from a linear 
regression analysis.  The average number of rPG per liposome observed from liposomes 
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containing 5% Ni-NTA is threefold higher than the plateau in Fig. 2.1a, which clearly 
demonstrates that the trend of saturation observed in Fig. 2.1a is not due to surface crowding.  
Rather, it is due to the limited number of Ni-NTA sites per liposome.  These results also suggest 
that one potential strategy to regulate the spatial densities of proteins on these liposome surfaces 
is to adjust the percentage of Ni-NTA-DGS lipids incorporated into liposomes. 
 
The above approach to estimate the average number of proteins on liposomes is an 
ensemble-based measurement, where we assume each liposome has an average number of lipid 
molecules, based on which to calculate liposome molarity and thus the number of rPG molecules 
per liposome.  Moreover, for the above approach to work, the fluorescence intensity of Alexa-
594 fluorophore should not change significantly upon conjugation onto liposomes through 
protein G, i.e., rPG free in solution and rPG conjugated on the surface of a liposome should have 
similar fluorescence intensity, otherwise any change in fluorophore quantum yield has to be 
taken into account when doing estimations using this approach, which is not trivial.  To provide 
an alternative and yet direct measurement for the spatial densities of rPG on individual 
liposomes, we have resorted to single-molecule fluorescence approach. 
 
As shown in Fig. 2.2a, we deposited purified rPG-conjugated liposomes on poly-L-lysine 
coated coverslips, and use epi-fluorescence imaging to directly visualize individual liposomes 
through excitation of the Alexa-594 fluorophore by a 592-nm laser.  Individual liposomes 
showed up in a dark background as bright spots.  These liposomes were prepared by incubating 
2.5 µg rPG with liposomes containing 1% Ni-NTA-DGS (0.44 µmol DMPC), followed by gel 
filtration.  Neither liposome samples alone nor free rPG alone at the same concentrations yielded 
these bright spots under the microscope.  Moreover, no fluorescent spots were visible when rPG 
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was incubated with liposomes without Ni-NTA-DGS, suggesting that these fluorescent spots 
were liposomes conjugated with rPG through Ni-NTA but not protein aggregates.  In order to 
determine the number of rPG molecules per liposome, we selected to work at a laser power of 
100 mW.  This illumination condition allowed us to collect the initial fluorescence intensity from 
individual spots, and the constant illumination of the sample under this condition also allowed us 
to observe the photobleaching of individual fluorophores with time.  As shown in Fig. 2.2b, these 
photobleaching events display a hallmark feature of ‘steps’, where the fluorescence persists for a 
finite time followed by a sudden decrease in fluorescence intensity.  These steps correspond to 
the photobleaching of individual molecules.  We have used a step-detection algorithm that we 
developed previously 30 to identify steps from these real-time fluorescence traces.  Measurement 
of this ‘step’ size yields the fluorescence intensity of a single Alexa-594 fluorophore, which can 
be used as an internal reference to convert the initial fluorescence intensity of individual 
liposomes to the number of Alexa-594 fluorophores, as we have done recently for individual 
HIV-1 virions using the same quantitation methodology31.  As shown in Fig. 2.2c, the histogram 
of the individual photobleaching step sizes for Alexa-594 molecules (N=163) could be well 
described by the sum of two Gaussians (black curve), one centered at 649 ± 136 analog-to-digital 
units (a.u., mean ± standard deviation) and the other centered at 1164 ± 235 a.u.  Under a 
statistical significance level of 5%, Pearson's Chi-square test 32 selected the double-Gaussian 
distribution (P-value=0.84) and rejected the single-Gaussian distribution (P-value=0.02) as the 
model to describe the data.  The difference in peak values is close to twofold.  As we have 
observed previously, the secondary peak may result from the photobleaching of two Alexa-594 
molecules that occurred almost simultaneously, which could not be resolved by either the finite 
camera exposure time or the step-finding algorithm 33,34.  The fluorescence intensity of a single 
Alexa-594 fluorophore can then be used to calculate the total number of Alexa-594 molecules 
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per liposome based on a ratio comparison 35,36 with the initial fluorescence intensity of Alexa-
594 associated with individual liposomes.  Fig. 2.2d shows the distribution for the number of 
rPG molecules per liposome gathered from this analysis.  It is very clear that the individual 
liposomes are heterogeneous in the number of rPG molecules per liposome, ranging from a value 
below 20 to a value above 100.  Under a typical statistical significance level of 5%, Pearson’s 
Chi-square test 32 selected a single-Gaussian distribution (p-value = 0.2249, shown in black 
curve) and strongly rejected Poisson distribution (p-value < 0.0001) as the model to describe the 
data.  The arithmetic mean value is 53, which is very close to the value of 57 ± 3 rPG molecules 
per liposome estimated using the ensemble approach as described above (Fig. 2.1a).  Therefore, 
the results from the single-molecule fluorescence measurements further support the use of the 
ensemble approach to estimate the average spatial density of proteins under our current 
experimental conditions. 
 
Characterization of the Average Spatial Density of mTFP on Liposomal Surface 
 
The B1 domain of the streptococcal protein G is a very small protein: even after the site-
specific labeling of the Alexa-594 fluorophore, the molecular weight is still less than 9kD.  To 
test if the above results for protein G may also be relevant to larger protein antigens, we have 
overexpressed and purified a green fluorescent protein variant, mTFP25, which carries a 
hexahistidine tag for attachment onto liposomes through Ni-NTA coordination chemistry.  This 
protein adopts a ‘β-can’25 structure that is typical of Green Fluorescent Proteins and the 
hexahistidine-tagged version of the protein has a molecular weight of 28 kD.   
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We prepared liposomes containing varied percentages of Ni-NTA-DGS, and incubated the 
purified mTFP proteins with various liposomes followed by gel filtration to remove free proteins.  
To develop an approach that is more applicable to generic protein antigens, we also decided to 
use the silver staining method instead of fluorescence to quantitate the amount of proteins 
present in the purified liposome samples.  This method entails a standard curve based on band 
intensities quantitated from a silver-stained polyacrylamide gel using the proteins of interest at 
various quantities.  The linear dependence between the band intensity and the quantity of mTFP 
protein (Fig. 2.5b) allows us to estimate the amount of mTFP proteins present in the purified 
liposome samples, by running the purified liposome sample on the same gel. 
 
As shown in Fig. 2.3a, the average number of mTFP molecules per liposome determined in 
this way shows a linear dependence on the percentage of Ni-NTA-DGS contained in the 
liposomes, consistent with the trend observed for rPG on liposomes (Fig. 2.1b).  With 20% Ni-
NTA-DGS, on average, over 600 molecules of mTFP can be conjugated per liposome.  It is 
worth noting that for 20% Ni-NTA-DGS in a liposome of 100 nm diameter, theoretically there 
are more than 17,000 Ni-NTA groups per liposome available for binding with hexahistidine-
tagged proteins.  Therefore, 600 molecules may not have reached the limit that one can conjugate 
on individual liposomes.  To obtain more insight on the capacity of individual liposomes for 
conjugation of mTFP, we have thus decided to carry out the following experiment: we prepared 
liposomes containing 20% Ni-NTA-DGS lipids, and then incubated these liposomes with 
increasing quantities of mTFP proteins.  After gel filtration to remove excess free proteins, we 
carried out three separate measurements on these purified liposomes: (1) run polyacrylamide gel 
to quantitate the amount of mTFP proteins based on silver staining (Fig. 2.5b); and (2) using 
Steward assay to determine phospholipid content and thus derive the moles of liposome based on 
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the average diameter measured from dynamic light scattering, and (3) using inductively coupled 
plasma optical emission spectrometry (ICP-OES) to directly measure Ni content for each 
purified liposome sample in order to verify the amount of Ni-NTA-DGS.   
 
As shown in Fig. 2.3b, the amount of mTFP conjugated on liposomes increased with 
increasing quantities of mTFP initially incubated with liposomes (filled circles), showing a trend 
of reaching a plateau.  Meanwhile, the percentage of Ni-NTA-DGS that we experimentally 
measured for these purified samples using ICP-OES (open circles) yielded an excellent 
agreement with theoretical expectations, with a mean and standard deviation of 20.3 ± 0.7 % 
among these samples.  It is worth noting that under these conditions, even for the highest 
quantities of mTFP we tried, the amount of Ni-NTA was still in excess, with a molar ratio of 3:1 
between Ni-NTA-DGS and the mTFP protein.  This result thus indicates that there were more 
Ni-NTA binding sites on liposomes than the amount of free mTFP available, and this trend of 
plateau is unlikely to be a result of limiting Ni-NTA-DGS quantity in liposomes.  More likely, it 
is due to the crowding of mTFP molecules on the liposomal surface.  The radius of gyration for a 
globular protein of 28 kD is close to 2 nm37.  For a liposome of 100 nm diameter, the upper limit 
on the number of mTFP molecules per liposome is thus estimated to be 2,500 with the 
assumption that the entire surface of the liposome can be fully occupied by arrays of mTFP 
molecules without significant vacancies in between.  This estimation thus supports our 
interpretation on the mechanism behind the trend of plateau observed in Fig. 2.3b (filled circles) 
and indicates that the epitope density on these liposomes can be fine controlled by adjusting the 
percentage of Ni-chelating lipids. 
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Stability of the Ni-NTA Noncovalent Conjugation Chemistry 
 
Although the use of Ni-NTA coordination chemistry is of great convenience considering 
the varieties of recombinant proteins that can be purified using hexahistidine technology, the 
noncovalent nature of this coordination chemistry may give rise to undesired drawbacks.  The 
binding affinity between hexahistidine-tagged proteins and Ni-NTA-modified surface has been 
reported to be 0.1-1 µM.38,39  In particular, Groves and coworkers have revealed that there is a 
great degree of heterogeneity in the Ni-NTA coordination complex formed between the 
hexahistidine tag and the nickel ions, which depends on the initial binding conditions and results 
in different off rates observed for proteins attached to supported lipid bilayer through this non-
covalent chemistry and a changing protein density with time.40 
 
To examine the stability of proteins conjugated onto liposome surface through this 
noncovalent chemistry, we have thus measured the dissociation of proteins from liposomes by 
direct observation using fluorescence microscopy.  This experiment was done by using the rPG-
conjugated liposomes, the same preparation of liposomes that we used in Fig. 2.2 for quantitation 
of the number of rPG molecules per liposome using the single-molecule fluorescence approach.  
The starting sample has 53 rPG molecules per liposome on average (Fig. 2.2d).  To monitor the 
kinetics of dissociation, the liposome sample was diluted 1,000 fold into PBS buffer on Day 0.  
The diluted sample was stored in dark in a polypropylene test tube for designated time at 22ºC 
and then aliquots were taken out for measurement of the protein density using the single-
molecule fluorescence approach as illustrated above, and also the size using dynamic light 
scattering.  Although the size of liposomes does not change over a two-week period (Fig. 2.5c), 
as shown in Fig. 2.4, the average number of rPG molecules per liposome dropped with 
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increasing days after the initial dilution (black circles).  The average number of rPG per liposome 
decreased from 53 ± 4 (Mean ± standard error) on Day 0 to 27 ± 3 after a week, and 13 ± 1 after 
two weeks.  In contrast, the liposome sample without dilution still had similar number of rPG 
molecules per liposome bound after two weeks (data not shown).  For comparison, we also 
prepared liposomes whose surface was conjugated with a peptide epitope using covalent 
maleimide-thiol conjugation chemistry (Materials and Methods) and used the same epi-
fluorescence imaging approach to quantitate the number of fluorophores per liposome.  After 
dilution of the liposome sample to the same concentration as that for rPG liposomes, no apparent 
decrease of the fluorophore number per liposome was observed over the same time period of two 
weeks (Fig. 2.4 open squares), suggesting that the epitopes are stably conjugated on the liposome 
surface.   
 
Discussion 
 
In this study, we have developed quantitative methods to measure the average spatial 
density of proteins on the surface of liposomes after conjugation.  Our method of ensemble 
estimation is supported by direct single-molecule measurement of protein densities on individual 
liposomes (Fig. 2.2).  Proximity of fluorophores is less an issue for our current quantitation using 
fluorescence, because even for the highest spatial density we have, 500 rPG per liposome (Fig. 
2.1b) the average distance between rPG molecules will be 8 nm, which is still large enough to 
prohibit quenching through energy transfer or complex formation.  Based on our studies, the 
spatial density of a protein that one can attach onto liposome surface is limited by the percentage 
of Ni-NTA-DGS under saturating protein conditions (Fig. 2.1a).  On the other hand, as the 
percentage of Ni-NTA-DGS increases, the spatial density of proteins will be eventually limited 
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by the surface crowding effect (Fig. 2.3b), i.e., the available liposomal surface will be fully 
occupied by the attached proteins.  These methods of density quantitation are not protein-specific 
and thus can be applied to protein-conjugated liposomes in general. 
 
Moreover, these quantitative studies revealed that the density of protein conjugation on 
liposomes can be fine controlled, and suggest a potential strategy for regulating the spatial 
density of epitopes on liposomes as particulate antigens, which is an important parameter for B 
cell antibody response and vaccination1.  This strategy entails the following important steps: (1) 
purification of target proteins containing specific tags or active groups for chemical conjugation; 
(2) liposome synthesis using a mixture of lipids, in which a small percentage of lipids carry 
specific and reactive head groups; (3) after liposome synthesis, use excess protein for  
conjugation to the outer surface of the liposome via the specific conjugation chemistry; (4) gel 
filtration to purify protein-conjugated liposomes away from excess proteins.  Compared to other 
alternative procedures, this strategy has the following advantages: (1) conjugation of protein post 
liposome synthesis helps to keep proteins in their native states and avoid their exposure to 
organic solvents used for liposome synthesis; (2) because of excess proteins used for 
conjugation, variation of the percentage of the specific lipid head-groups will thus allow the 
regulation of protein density.  Systematic enumeration of the specific lipid percentage may allow 
formation of liposomes with surface epitopes at discrete densities, which would be very 
important tools for antibody-based vaccine development.  
 
As we mentioned in the introduction, our current quantitation of protein density is an 
average over a single particle.  These proteins attached onto liposome surface may still undergo 
two-dimensional diffusion, which may allow formation of protein clusters and a high local 
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surface density.  Whether this may occur as a result of B cell recognition remains to be 
investigated in the future.  
 
In this study, we have compared two different methods of epitope conjugation onto the 
outer surface of liposomes: Ni-chelation chemistry versus Michael addition of a thiol group to a 
maleimide.  As we showed for Ni-NTA coordination chemistry, due to its noncovalent nature, 
the spatial density of proteins is not stable but decreases upon dilution (Fig. 2.4).  This is not 
desired for the long-term storage of this formulation nor in vivo vaccination, because the time-
dependent change of epitope density will confound the interpretation of the immunogenicity data 
based on liposome particles that use this noncovalent chemistry.  Second, it is worth noting that 
substantial studies in literature have documented the adverse biological effects of nickel ions in 
vivo, which include tissue inflammation that is correlated with their distributions 41, allergy 42, 
toxicity and carcinogenicity 43-45.  Third, the hexahistidine tags might also be immunogenic in 
vivo, whose safety profile remains to be demonstrated.  As a result, Ni-chelating liposomes may 
encounter significant safety challenges towards a final clinical product.  In contrast, the 
alternative approach using maleimide-thiol reaction to conjugate epitopes onto liposome surface 
will yield a spatial density that is stable over time in vitro (Fig. 2.4).  Moreover, the maleimide-
thiol conjugation is less likely to be a regulatory concern because several FDA approved drug 
products contain maleimide-thiol conjugates 46-48.  Also, this chemistry has been widely used in 
the conjugation of drugs to macromolecules.  There is a wide interest in the pharmaceutical and 
biotech industry to further optimize the chemistry of this conjugation to improve drug products 
49,50.  We thus expect synergistic efforts towards the use of this conjugation chemistry.  
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Lastly, we emphasize that our strategy presented above to regulate the spatial density of 
surface epitopes on liposomes should also be applicable to the maleimide-thiol reaction 
chemistry, where maleimide-containing lipids can be doped into liposomes at varied percentages 
during synthesis, and conjugation with excess proteins that contain specific and accessible thiol 
groups will thus allow formation of liposomes bearing varied densities of epitopes.  Based on the 
stability comparison for the protein conjugation (Fig. 2.4), and the safety issues that we have 
outlined above, we argue that the Michael addition of thiol to maleimide is a superior strategy 
than Ni-NTA coordination chemistry to conjugate epitopes onto liposomes for elicitation of 
antibody responses.  Future experiments should explore maleimide-thiol reaction chemistry to 
conjugate epitopes at regulated spatial density on liposome surface and test these liposomal 
particles in animals for optimal B-cell antibody response. 
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2.6. Tables and Figures 
 
A. Characterization of Ni-chelating liposomes by dynamic light scattering.  
 
 
 
B. Characterization of Ni-chelating liposomes before and after rPG association by 
dynamic light scattering.  
 
 
 
Table 2.1. Characterization of Ni-chelating liposomes of different percentage of Ni-
NTA lipid before and after rPG association by dynamic light scattering.   
 
(one representative out of three results).   
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A. Coupling of rPG at various initial quantities to liposomes of 1% Ni-NTA-DGS. 
 
 
 
 
B. Coupling of 30 μg rPG with liposomes of various percentages of Ni-NTA-DGS. 
 
 
 
 
 
C. Coupling of 40 μg mTFP with liposome of various percentages of Ni-NTA-DGS. 
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D. Coupling of mTFP at various initial quantities to liposomes of 20% Ni-NTA-DGS. 
 
 
 
 
 
Table 2.2. The coupling efficiency of proteins onto liposomes together with the yield 
of lipid recovery after size-exclusion chromatography for each protein coupling 
reported in this work.  
 
The subpanels (A-D) are from experiments reported in Fig. 2.1a, Fig. 2.1b, Fig. 2.3a and Fig. 
2.3b, respectively. 
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Figure 2.1. Characterization of rPG-conjugated liposomes using ensemble 
approach.  
 
(a) The average number of rPG per liposome as a function of the initial input quantity of rPG 
during incubation with liposomes that contain 1% Ni-NTA-DGS.  The error bars are standard 
deviations from three independent repeats of the same experiment.  The solid line serves as a 
guide for the eye only.  (b) The average number of rPG per liposome as a function of the 
percentage of the Ni-NTA-DGS incorporated into the liposomes (a representative of two). The 
solid line is a result of linear regression for the experimental data points. 
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Figure 2.2. Characterization of rPG-conjugated liposomes using a single-molecule 
fluorescence approach.  
 
These liposomes were prepared by incubating 2.5 µg rPG with liposomes containing 1% Ni-
NTA-DGS (0.44 µmol DMPC), followed by gel filtration.  Immediately before imaging, the 
liposome sample was diluted 1000-fold in PBS and deposited onto a coverslip. (a) A snapshot of 
the epi-fluorescence image of rPG-conjugated liposomes deposited on poly-L-lysine coated 
coverslip.  The scale bar represents 10 µm.  (b) Representative time trajectories of single-
molecule photobleaching recorded from individual rPG-conjugated liposomes. (c) Histogram of 
the individual photobleaching step sizes for Alexa-594 molecules identified from the 
fluorescence time courses (b) using a step-finding algorithm (n = 163), which could be described 
by the sum of two Gaussians (black curve). (d) Histogram for the number of rPG molecules per 
liposome based on the initial fluorescence intensity of individual liposomes normalized by the 
average fluorescence intensity of a single Alexa-594 fluorophore (N = 45). The solid line is a fit 
to a Gaussian probability density function. 
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Figure 2.3. Characterization of mTFP-conjugated liposomes.   
(a) Average number of mTFP per liposome as a function of the percentage of the Ni-NTA-DGS 
incorporated into the liposomes.  The various liposomes were prepared by incubation of the same 
moles of liposomes (0.07 µmol DMPC for liposomes with 5% Ni-NTA-DGS) with 40 µg of 
mTFP, followed by gel filtration to remove free mTFP proteins.  (b) Left y-axis: the average 
number of mTFP molecules per liposome as a function of the initial mTFP input during 
incubation with liposomes containing 20% Ni-NTA-DGS.  The initial amounts of liposomes 
were all identical among different samples (0.18 µmol DMPC). Right y-axis: the percentage of 
Ni-NTA-DGS incorporated into liposomes measured by ICP-OES.  The error bars are standard 
deviations from three independent repeats of the same experiment. 
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Figure 2.4. The kinetics of epitope dissociation from individual liposomes.   
The average number of rPG molecules or fluorescent TNF-α peptides per liposome measured 
from single-molecule fluorescence approach as a function of the days after the initial dilution of 
the liposome samples.  For each data point, 45 individual liposomes were randomly selected 
from fluorescence images for each sample and analyzed for the average number of fluorescent 
epitopes per liposome.  The error bars represent 1.96 standard error of the mean. 
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Figure 2.5. Supplementary figures.  
a. Standard curve of rPG concentration from 0.74 μg/ml to 2.96 μg/ml. The solid line shows the 
linear regression analysis performed on the fluorescence intensity of rPG as a function of its 
concentration, which yields an R-squared value of 0.997. The error bars are standard deviations 
from three independent repeats of the same experiment. b. Standard curve for measurement of 
mTFP concentration in purified liposome samples with band intensities quantified from a silver-
stained SDS-PAGE using ImageJ. The solid line shows the linear regression analysis performed 
on the band intensity of mTFP as a function of the loaded protein mass, which yields an R-
squared value of 0.981. The error bars are standard deviations from three independent repeats of 
the same experiment. c. Size of rPG-conjugated liposomes as a function of time after dilution. 
The error bars are standard deviations from three independent measurements.  
a b 
c 
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Chapter 3 
 
Self-antigens Displayed on Liposomal Nanoparticles at High 
Surface Density Elicit Class-switched Autoreactive Antibodies 
Independent of T-cell Help 
 
 
 
 
3.1. Abstract 
 
Epitope density has a profound impact on B cell responses to particulate antigens, the 
molecular mechanisms of which remains to be explored.  Early studies led by Zinkernagel and 
Schiller, respectively, have established that multivalent display of antigens on viruses or viral-
like particles can overcome B-cell tolerance and elicit potent autoreactive antibodies in a T-cell 
dependent manner.  However, how epitope density drives B cell activation in this process 
remains largely unknown.  To dissect the role of epitope density in this process, we have 
synthesized a series of liposomal particles, similar to the size of viruses, that display a model 
self-antigen peptide at defined surface densities.  Immunization of mice using these particles 
consistently elicited both IgM and class-switched IgG antibodies that are reactive towards the 
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self-antigen peptide.  However, the IgG response shows no boosting effect upon repeated 
immunizations, suggesting the lack of T-cell involvement in this process.  In transgenic mice 
lacking either functional T-cell receptors or MHC class II molecules on B cells, the liposomal 
particles elicited similar levels of IgM and IgG responses, confirming that this is a T-independent 
process.  Remarkably, the titer of the IgG elicited in these experiments can be increased by 1000-
fold upon replacement of liposomes by bacteriophage Qβ virus-like particles that display the 
same self-antigen peptide at comparable epitope densities, and this enhancement is lost almost 
completely in transgenic mice lacking either T-cell receptors or MHC class II molecules on B 
cells.  In conclusion, high epitope density alone can trigger antibody class switching in B cells, 
and the extraordinary immunogenicity of viral-like particles relies in large part, on their ability to 
effectively recruit T cell help. 
 
 
3.2. Introduction 
 
Often, foreign particulate antigens such as viral particles can effectively prime the immune 
system for elicitation of protective antibody responses, with a few exceptions.  This fact forms 
the basis for the majority of licensed antiviral vaccines 1.  However, how a particulate antigen 
such as a viral particle activates the immune system to bring about the protective antibody 
responses, especially at quantitative and mechanistic level, remains largely uncharacterized.  One 
of the breakthroughs in our understanding of this question was put forward by Bachmann et al. 2, 
who showed that epitope density has a profound impact on B cell responses to antigens.  
Remarkably, the envelope glycoprotein displayed on the surface of vesicular stomatitis virus can 
break the tolerance of B cells in transgenic mice that express the same glycoprotein under the 
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control of H-2K promoter 2.  Along a similar vein, studies led by Schiller showed that potent and 
long-lasting autoreactive IgG antibodies were elicited in mice upon immunization with self-
antigens incorporated or conjugated to papillomavirus-like particles 3-5.  These discoveries have 
led to potentially exciting applications of these techniques in efforts to elicit therapeutic 
antibodies through vaccination approach 6,7.  However, at fundamental mechanistic level, there 
remain questions unanswered regarding the extraordinary immunogenicity of these viruses or 
viral-like particles.  Specifically, what are the molecular components or quantitative features in 
these particles that are required for the potent B cell activation?  If collaboration with other 
immune cells is also required to yield the antibody response, to what extent does the production 
of these antibodies rely on those cells?  Answers to these questions can not only help the design 
and engineering of vaccines, but also help understand the spectra of host immune responses to 
viral pathogens.   
Among various features shared by the particles listed above, epitope density appears to be 
a dominant parameter in the quality of the antibody response.  Ensemble estimations based on 
RNA and proteins present in viral particles yielded approximately 500 glycoproteins per 
vesicular stomatitis viral particle 8, while papillomavirus displays 360 copies of the major capsid 
protein L1 per particle based on a cryoelectron microscopy study9.  Although the former is an 
enveloped virus while the latter is an icosahedral virus, both viruses display high number of 
viral-specific epitopes per particle, which is in fact a feature shared by most of the human viral 
pathogens with licensed vaccines 1.  Chackerian et al. showed that reduction of epitope density 
on papillomavirus-like particles significantly decreased the IgG autoantibody production 3, 
highlighting the critical role of high epitope density in breaking the B cell tolerance.  However, 
high epitope density alone does not seem to entail the full story.  It was known early on that very 
high density of antigens could induce B cell tolerance both in vitro and in vivo 10,11.  A recent 
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study of mouse B cells also suggested that too high epitope density in the absence of immediate 
T-cell help may trigger B-cell death instead of activation 12; 
 
In order to understand quantitatively and mechanistically B cell responses to particulate 
antigens and define the role of epitope density in this process, we have taken a ‘deconstructive’ 
approach, by chemically synthesizing particulate antigens similar to the size of viruses, and use 
these particles for immunization in mice.  We chose liposomes as carriers for the epitope of 
interest because (1) the nonimmunogenic nature of liposomes by themselves, and (2) the 
versatility of liposomes in epitope conjugation and engineering 13.  In particular, as we have 
shown recently 14, the epitope of interest can be conjugated onto the surface of these particles in 
a controlled fashion which yields particles with varied epitope densities, which would be one of 
the important tools to unravel the role of epitope density in this process.  As we show, these 
particles alone can elicit IgG autoreactive antibody responses in a manner that depends on 
epitope density.  To the best of our knowledge, this is the first time that an antigen, upon 
conjugation to liposomes at high epitope density, is shown to induce class-switched antibody 
responses in the absence of T-cell help.  At comparable epitope density, replacement of 
liposomes with bacteriophage Qβ viral-like particles can dramatically enhance the titer of the 
IgG response.  In comparison to liposomes, the superior immunogenicity of viral-like particles 
originate almost exclusively from their extraordinary capability to recruit MHC Class II 
dependent T-cell help after B-cell activation.  Our study has thus helped answer a fundamental 
question in immunology regarding B-cell activation by particulate antigens and offered valuable 
insights to future vaccine design targeting self-antigens. 
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3.3. Materials and Methods 
 
Synthesis of liposomes and antigen conjugation 
 
Liposomes were prepared using oil-in-water microemulsion precursor followed by 
membrane extrusion as described1–3. Three different lipids of designated molar ratios were used 
in the synthesis of liposomes: DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine), DSPE-
PEG (2000) maleimide (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- [maleimide 
(polyethylene glycol)-2000] (ammonium salt)) and cholesterol (Avanti lipids).  Briefly, lipid 
mixture (7.5 4mol in total) in chloroform were added to a round-bottom bottle and desiccated by 
vacuum to form a thin film at the bottom. 1mL HEPES buffer (50mM HEPES, 150mM NaCl, 
pH6.9)15 was added to hydrate the lipid film through vortex and short bursts of sonication (30s) 
in water bath.  After hydration, the lipid film resuspension was extruded using polycarbonate 
membrane with pore sizes of 1000 nm and 100 nm sequentially for ten times each.  Synthesized 
liposomes were incubated with a peptide from mouse tumor necrosis factor α (TNF-α peptide,  
CSSQNSSDKPVAHVVANHQVE, 95% purity, Biomatik Scientific) at a chosen molar ratio 
between the maleimide and the peptide.  The N-terminal cysteine of the peptide was engineered 
for the purpose of maleimide conjugation.  After overnight incubation at room temperature, the 
liposome peptide mixture was applied to Sepharose CL-4B gel filtration column, as we described 
previously 14, to separate TNF-α conjugated liposomes from unconjugated free peptide.  The 
peptide-conjugated liposomes were stored at 4°C in PBS. 
 
 Quantitation of average peptide density on liposomes 
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To quantitate the average density of TNF-α peptide covalently conjugated on liposomes, 
our strategy is to estimate the concentration of liposome and peptide respectively for the 
liposomes purified through gel filtration column.  The ratio between the two concentrations 
represents the average number of TNF-α peptide per liposome, as we described recently 14.  
Briefly, to estimate the concentration of liposomes, we used the established Stewart assay16 to 
determine the phospholipid content in the purified liposomes, based on which the molarity of the 
liposomes can be further estimated as described 14.  For each liposomal sample, 20 µL purified 
liposomes were added to 500 µL of chloroform in a clean glass tube, and then 500 µL 
ferrothiocynate solution containing 0.1 M ferric chloride hexahydrate and 0.4 M ammonium 
thiocyanate was added.  The mixture was vigorously vortexed for 20 seconds and then 
centrifuged for 10 minutes at 1000X g. The lower chloroform layer was then taken for absorption 
measurement at 470 nm. The phospholipid concentration was then calculated based on standard 
curves constructed from known quantities of DMPC and m-DSPE-PEG, respectively, taken into 
account the compositions of the two lipids in the liposome samples.  To measure the 
concentration of TNF-α peptide conjugated on liposomes, we used bicinchoninic acid (BCA) 
protein assay 17.  Briefly, 100µL of the liposome sample was incubated with 2 mL BCA solution 
at 60 °C for 30 minutes before absorption measurement at 562nm.  8% SDS was also included in 
this mixture to minimize the interference of lipid to BCA assay as reported 18.  The TNF-α 
peptide concentration was calculated based on the comparison with a standard curve constructed 
from known quantities of TNF-α peptide under the same BCA assay conditions. 
 
Stability of epitope density in serum-containing media 
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Liposome of 20% maleimide-lipid was synthesized and conjugated with TNF-α peptide as 
described above. After conjugation, liposome20%-m- TNF-α was added with equal volume of fetal 
bovine serum for incubation at room temperature. After 1, 3, 5, and 7 days of incubation 
respectively, a fraction of liposome-serum mixture is taken and loaded to size exclusion column 
for purification of liposomes. After purification, the liposomes are evaluated by the Stewart 
Assay for quantitation of lipid concentration. Liposomes of same amount of lipid taken from 
different timepoints of serum incubation are loaded to Tricine-SDS gel for gel electrophoresis. A 
Tricine-SDS-PAGE protocol reported was followed here.  For optimized bands of proteins and 
peptides <5 kDa, we used 16% acrylamide separating gel with 1cm of 10% spacer gel and 4% 
stacking gel. The running setting is 120 V for initial 20 mins and 180 V for approximately 90 
minutes till the loading dye runs out of gel. Silver staining was carried out for quantitation of 
peptides and proteins on the gel.  
 
Mice inoculations 
 
All animal procedures were approved by the University of Michigan Animal Care and Use 
Committee.  Female C57BL/6 mice (³8 weeks, Jackson Laboratory) were used for inoculations. 
Prior to inoculation, all injection samples were filtered through 0.45 µm pore size membrane to 
eliminate potential microbial contamination. 100 µL samples were injected to each mouse 
subcutaneously, 50 µL on each flank.  The immunization was boosted on days 14 and 28 using 
the same materials. Mouse blood was collected submentally using Microvette serum collection 
tube (Sarstedt) three days before the first injection, and 11 days after each immunization.  The 
serum was harvested by centrifugation at 10,000 g for 10 minutes and immediately frozen and 
stored at -20°C.  
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Two strains of transgenic mice were purchased from Jackson Laboratory: Tcrbtm1Mom/ 
Tcrdtm1Mom (#002122) and Ciitatm1Ccum (#003239).  Tcrbtm1Mom/ Tcrdtm1Mom mice are deficient in 
alpha beta and gamma delta T-cell receptors 19, while Ciitatm1Ccum mice do not have MHC class II 
molecules on the surface of splenic B cells or dendritic cells 20. Transgenic mice were housed in 
germ-free environment and immunization protocol were carried out as described above for 
C57BL/6 mice. 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
 
Blood serum was tested for ELISA in order to quantitate B cell antibody responses from 
various immunizations.  96-well plates (Nunc MaxiSorp, Invitrogen) were coated overnight at 
4°C with 5 µg of TNF-α peptide in PBS. After blocking with 1% BSA (Bovine Serum Albumin, 
Fisher) in PBS, mouse serum of different dilution factors (1: 100, 1: 400 and 1:1600) was added 
to each well for incubation at 22°C for 2 hours. After three washes using PBS with 0.05% 
Tween-20, secondary anti-mouse-IgG-HRP antibody (# 616520, Life technologies) or anti-
mouse-IgM-HRP antibody (# 626820, Life technologies) was added in blocking buffer at 1:5000 
dilution and incubated for 1 hour at 22°C.  Following three washes, 100 µL TMB substrate 
(3,3',5,5'-Tetramethylbenzidine, Thermal Scientific) was added to each well and incubated in 
dark for 10 minutes.  The reaction was stopped by addition of 100 µL 2M sulfuric acid in each 
well.  The optical density of each well at 450nm was measured using a microplate reader (Bio-
Tek Synergy HT).  All the OD values reported were background subtracted by comparison 
between two wells that were coated with TNF-α peptide and PBS, respectively.  Similarly, for 
ELISA using TNF-α protein as the bait, 200 ng of recombinant murine TNF-α protein (≥ 98% 
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purity, #315-01A, PeproTech) was coated in each well and the rest procedures were carried out 
as described above.  
 
To determine the titers of anti- TNF-α antibodies, we used serial dilution of serum (from 
1:100 dilution to 1:1638400 by dilution factor of 4) for ELISA with TNF-α peptide or protein for 
plate coating. Cutoff values are calculated as reported: Cutoff = Χ6 + 89 ∙ ;, where X̄ and SD is 
the mean and standard deviation of control well OD reading values, ; is standard deviation 
multiplier corresponding to different confidence levels (Here, ; = 2.631 when the number of 
control wells is 4 and confidence level is 95%). The titer value is determined as the highest 
dilution factor of serum that still yields OD450 reading value higher than cutoff value in ELISA.  
 
 
3.4. Results and Discussion 
 
Liposome-based particulate antigens that carry epitopes of varying density 
 
To obtain a quantitative and mechanistic understanding of B cell responses to particulate 
antigens such as viruses, we decided to choose liposomes as our platform for antigen design.  
The unique advantage of using engineered liposomal particles as opposed to a specific virus is 
threefold: (1) the use of liposomes by themselves will not elicit an immune response and 
therefore provide a baseline for quantification of immunogenicity; (2) it allows us to use defined 
components to build a particle that mimic certain features of a natural virus particle and therefore 
no ambiguity on the constituents of the input antigen; and (3) it allows us to use model antigens 
(such as the TNF-α peptide used in this study) to systematically investigate the individual 
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contribution of various virus features on B-cell responses, including epitope density, the presence 
or absence of T-cell epitope and Toll receptor (TLRs) ligands, because these different features 
can be built into a liposomal nanoparticle in a controllable fashion. 
 
In current study, we have selected DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine) 
as the major lipid for construction of our liposomes, which has a phase transition temperature of 
23°C 21 and therefore offers ease in extrusion through polycarbonate membranes.  For 
conjugation of B-cell epitopes onto the surface of liposomes, we chose a sequence of 20 amino 
acids from mouse tumor necrosis factor α (TNF-a) as our model self-antigen.  This sequence, 
SSQNSSDKPVAHVVANHQVE, corresponds to amino acids 83-102 of mouse TNF-a.  Based 
on crystal structures of the highly homologous human TNF 22,23, the C-terminal half of the above 
sequence is predicted to be solvent exposed and contain critical residues that are directly 
involved in binding with TNF receptors22.  Therefore, antibodies directed against this peptide are 
expected to bind the TNF-α protein and potentially block TNF-α and receptor interactions.  
Indeed, Chackerian et al. were able to elicit potent and long-lasting autoreactive TNF-α 
antibodies in mice using this peptide fused to a truncated form of streptavidin that is conjugated 
to biotinylated bovine papillomavirus-like particles 5, suggesting the presence of a mouse B-cell 
epitope in this peptide.  The lack of Cysteine in the above peptide sequence allows us to engineer 
a single Cysteine at the N-terminus of the peptide for conjugation of this peptide to the surface of 
liposomes using maleimide chemistry in an orientation that exposes its C-terminal residues.  For 
this maleimide chemistry, we have specifically chosen DSPE-PEG(2000) maleimide as the 
phospholipid for incorporation into liposomes.  The presence of polyethylene glycol chain 
between the lipid head group and the maleimide moiety can increase the residence time of 
liposomes in the bodily fluid as demonstrated for many liposome systems 24-28.  
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To check the covalent conjugation of the TNF-α peptide onto the liposomes, we ran 16% 
polyacrylamide gel and subjected the gel to silver staining.  As shown in Fig. 3.1a, two bands 
were shown, the peptide itself has a molecular weight of 2kD, and the DSPE-PEG(2000) 
maleimide lipid has a molecular weight of 2941.605 Dal.  Thus this is exactly as expected for a 
1:1 conjugation of the peptide onto the lipid.  We have also characterized these liposomal 
particles using dynamic light scattering (DLS).  As shown in Fig. 3.1b, the DLS data show a 
well-defined peak around 153 nm for peptide conjugated particles, which compares with 137 nm 
for bare liposomes, suggesting that the peptide may form a dense layer on liposomal surface 
under this set of conditions.  Consistent with this notion, quantitation of protein content in the 
purified liposomes (Materials and Methods) revealed 6,030 molecules of TNF-α peptide per 
liposome on average, which yields a density of 8.2×104 peptides/µm2 that is even more than 
twofold higher than the epitope density on papillomavirus-like particles (3.2×104 peptides/µm2) 
1.   
 
In order to test the effect of epitope density on B cell responses, it is necessary to prepare 
liposome particles with varied densities of epitope peptides.  To this end, we have systematically 
changed the mole percentage of the DSPE-PEG(2000) maleimide from 1.1 to 20% that we 
included during liposome synthesis.  After conjugation of the TNF-α peptide, these liposomes 
were purified through gel-filtration column and the epitope density was measured as described 
(Materials and Methods).  As shown in Fig. 3.1c, the epitope density on these liposomes display 
a monotonic increase with increasing percentage of the DSPE-PEG(2000) maleimide lipids.  
This dependence can be well described with a linear dependence (the black line in Fig. 3.1c), 
yielding R-squared value of 0.9922.  Specifically, the epitope density decreased to 357 for 
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liposomes containing 1.1% maleimide lipids, which is 6.6-fold lower than the epitope density on 
papillomavirus-like particles. 
 
Because the epitope density is a critical parameter that we will evaluate for B cell 
responses, we have repeated the synthesis of liposomes with 20% maleimide lipids, in order to 
check the reproducibility of the resulting epitope density.  As shown in Fig. 3.1d, for liposomes 
synthesized from 4 independent repeats of the same synthesis and conjugation procedure, they all 
yielded an epitope density around 6,000 TNF-α peptides per liposome on average, 6030.0 ± 
428.4, suggesting a very good reproducibility of our procedure. 
 
Lastly, because these liposome particles will be used in vivo for mouse immunizations, it is 
important that the epitope density is relatively stable in biological milieu so that the data can be 
interpreted with confidence.  In presence of 50% fetal bovine serum, liposome size remained 
constant with slight increase over a week as shown in Fig. 3.1e. The conjugated TNF-α peptide 
density on liposome also remained at a similar level over time, indicated by SDS-PAGE result in 
Fig. 3.1f, g.    
 
TNF-α peptides conjugated on liposomal surface elicit autoreactive IgG antibody in 
wild-type mice 
 
To examine whether TNF-α-peptides conjugated on liposomal surface (p-liposome) can 
elicit autoreactive antibodies, we immunized mice with p-liposomes prepared with 20% 
maleimide lipids (p-liposome20%-m), which displayed ~6,000 TNF-α-peptides per liposome on 
average.  Each group of mice received three doses of p-liposome20%-m, each dose containing 4.5 
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µg TNF-α-peptide.  Antibody responses were measured by ELISA using serum collected 11 days 
after each inoculation.  As shown in Fig. 3.2a-b, p-liposome20%-m elicited both IgM and IgG 
responses towards the TNF-α-peptides after just one dose.  Both responses are significantly 
higher than either the PBS or bare liposome control, and also significantly higher than those 
elicited by soluble TNF-α-peptides at the same dose (4.5 µg).  In fact, the levels of IgM and IgG 
responses from the soluble TNF-α-peptides are statistically indistinguishable from those of PBS 
or bare liposome controls, consistent with the fact that this peptide by itself is a bona fide self-
antigen and no apparent antibody responses were elicited upon immunization.  The results shown 
in Fig. 3.2a-b also suggest that upon conjugation of the peptide to a liposomal nanoparticle, it 
becomes immunogenic and can induce class-switched IgG antibody responses, even though the 
liposomal nanoparticles by themselves are not immunogenic. 
 
To further examine the antibody responses elicited by p-liposome20%-m, we continued to 
measure both IgM and IgG responses after the second and third immunizations.  As shown in 
Fig. 3.2c, the IgM response from p-liposome20%-m declined after successive injections, although 
the levels of responses were still distinguishable from those from soluble peptides.  In contrast, 
the IgG response from p-liposome20%-m was almost constant after the second and third 
immunizations, and remained much higher than those from soluble peptides (Fig. 3.2d).  The 
steady level of IgG responses after successive immunizations suggests the lack of apparent 
antibody affinity maturation or B cell clonal expansion, which is in sharp contrast to the boosting 
effect typically observed for foreign antigens. 
 
To examine the duration of the above antibody responses elicited by p-liposome20%-m in the 
absence of further immunizations, we continued to measure both IgM and IgG responses from 
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these animals up to 18 weeks after the first immunization.  As shown in Fig. 3.2e, the IgM 
response from immunized animals continued to decline and became indistinguishable from that 
of the soluble peptide by Week 10.  The IgG response also declines, although at a slower pace 
compared to that of IgM and became indistinguishable from that of the soluble peptide by Week 
14 (Fig. 3.2f).   
 
The above results revealed that a self antigen, once conjugated onto the surface of a 
liposomal nanoparticle, can elicit both IgM and IgG antibody responses that are much higher 
than those from soluble peptide controls at the same antigen dose.  To further examine the 
dependence of this immunogenicity on epitope density, we immunized C57BL/6 mice using p-
liposomes prepared with varied percentages of maleimides.  They are p-liposomes prepared with 
6.6% maleimides (p-liposome6.6%-m), p-liposomes prepared with 2.2% maleimides (p-
liposome2.2%-m), and p-liposomes prepared with 1.1% maleimides (p-liposome1.1%-m), which 
displayed 2479, 729, 357 TNF-α-peptides per liposome on average (Fig. 3.1c).  Together with p-
liposome20%-m and soluble peptide control, a total of five groups of mice were immunized.  
Throughout these immunizations, the peptide dose was kept the same (4.5 µg TNF-α peptide).  
Three immunizations were performed for each group, and the antibody responses were measured 
starting 11 days after the first immunization.  As shown in Fig. 3.3a, the IgM response from 
these various liposomes showed a clear dependence on epitope density: the lower epitope 
density, the lower IgM response.  Although for p-liposome1.1%-m, the IgM response is still 
statistically higher than that from soluble peptides.  Similarly, the IgG response from these 
liposomes also showed a clear dependence on epitope density:  the lower epitope density, the 
lower IgG response.  However, quantitatively, this decrease in IgG response follows a different 
trend from that of IgM response.  In going from p-liposome20%-m to p-liposome2.2%-m, IgM 
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response is almost unchanged, but the IgG response has dropped by fivefold (Fig. 3.3b).  For p-
liposome1.1%-m, the IgM response remains clearly distinguishable from that from soluble peptides 
at the same dose, however, the IgG response is indistinguishable from that of soluble peptide.  
These results reveal that IgG response is more sensitive to the change in epitope density than 
IgM responses.  In particular, even though a liposome has 357 TNF-α peptide on average, it is 
incapable of eliciting an autoreactive IgG response, which clearly shows the dependence of 
immunogenicity on the epitope density. 
 
All the immunization experiments that we have reported above were conducted in the 
absence of other immunostimulatory substance.  To examine the effect of Toll-like receptor 
activation on the above processes, we then performed immunizations using the aforementioned 
liposomes but in the presence of CpG.  For each immunization, 20 µg CpG was mixed with p-
liposomes and then administered into the animals.  The immunization still follows the same 
schedule as before and blood were collected at designated time for ELISA.  As shown in Fig. 
3.3c, all four p-liposomes induced very similar levels of IgM response, suggesting that the 
presence of CpG weakens the sensitivity of IgM response to epitope density.  Similarly for IgG, 
three groups of p-liposomes induced the same levels of IgG response within error (p-
liposome20%-m, p-liposome6.6%-m, and p-liposome2.2%-m).  The IgG response elicited by p-
liposome1.1%-m remains the lowest among the four groups of liposomes, but in the presence CpG, 
this IgG response is clearly significantly higher than that from soluble peptide control, which is 
in contrast to Fig. 3.3b, where p-liposome1.1%-m was incapable of eliciting an IgG response above 
background.  These results suggest that the presence of CpG will likely modulate the sensitivity 
of B cells to epitope density.  Specifically, the presence of CpG will sensitize B cells towards 
low epitope density, which is true for both IgM and IgG responses. We have continued to 
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monitor these animals for both IgM and IgG responses for longer time points.  As shown in Fig. 
3.9, IgG response did not show any boosting effect upon successive immunizations, which is true 
for all these liposomal preparations.  In addition, both IgM and IgG response drops with time, 
consistent with the pattern we observed in Fig. 3.2e-f. 
 
TNF-α peptides conjugated on virus-like particles elicit stronger autoreactive IgG 
antibody through T-cell help 
 
Even in the presence of CpG, it did not escape our attention that the titers of IgG response 
from these liposomes are only on the order of 102 ~ 103, which is much lower than the IgG titer 
reported for the same peptide but noncovalently conjugated to papillomavirus-like particles5.  To 
examine the mechanisms behind this apparent difference, we have thus conjugated the TNF-α 
peptide to bacteriophage Qβ viral-like particles (VLPQβ) using heterobifunctional crosslinker 
SMPH.  Bacteriophage Qβ has been used as an antigen presentation platform for elicitation of 
antibodies against self antigens both in mouse and in limited human clinical trials.  The single 
available thiol group present in our synthetic TNF-α peptide allows us to conjugate these 
peptides to the surface of VLPQβ that is derivatized by SMPH. The excess free peptide was 
removed by passing the reaction mixture through Amicon filtration units 3 times.  As shown in 
Fig. 3.4a in a silver stained gel to monitor this conjugation reaction, the SMPH-derivatized 
VLPQβ before conjugation with TNF-α peptide showed a major band around 15 kD, which 
corresponds to the molecular weight of Qβ major coat protein.  Upon crosslinking with TNF-α 
peptide, a series of bands were seen on the gel, which matches with the expected molecular 
weights for the coat protein conjugated with one TNF-α peptide, two TNF-α peptides, and so on.  
Based on silver staining intensity, we estimated that on average there are 260 TNF-α peptides per 
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VLPQβ particle, which yields an epitope density of 132,300 molecules/µm2.  This epitope density 
is about two thirds of the epitope density on p-liposome20%-m.  We have also characterized these 
VLPQβ particles using DLS.  As shown in Fig. 3.4b, the DLS data show a well-defined peak 
around 42 nm for peptide conjugated particles, which compares with 36 nm for underivatized 
VLPQβ particles, suggesting that the peptide may form a dense layer on VLPQβ surface which is 
also consistent with our estimation for the peptide density on these particles. 
 
We then used these peptide conjugated VLPQβ particles (p-VLPQβ) to immunize C57BL/6 
mice.  In these experiments, we followed the same immunization schedules as we did for p-
liposomes.  However, in order to compare the immune responses elicited by p-VLPQβ to those 
previously published in literature using papillomavirus-like particles, we have used p-VLPQβ 
containing 0.5 µg TNF-α peptides for each animal, which was the peptide dose published 
previously using papillomavirus-like particles.  This peptide dose was ninefold lower than those 
we employed in p-liposomes above, and thus for fair comparison, we also immunized C57BL/6 
mice using p-liposome20%-m containing 0.5 µg TNF-α peptides for each animal.  As shown in 
Fig. 3.5a, dose decrease for p-liposome20%-m elicited a marked lower IgM response compared to 
that from p-liposome20%-m containing 4.5 µg TNF-α peptides.  The p-VLPQβ, on the other hand, 
elicited much higher IgM responses than p-liposome20%-m.  Remarkably, for IgG responses, 
under the same dilution of 1:100, the p-VLPQβ elicited IgG responses that clearly saturated the 
OD reading at 450 nm (Fig. 3.5b).  Control experiments using a simple admixture of VLPQβ and 
the soluble TNF-α peptide at the same particle and peptide doses did not elicit any IgM or IgG 
response above the background, clearly revealed that it is the conjugation of the TNF-α peptide 
onto the VLPQβ and presentation of the peptide in the context of these particles that matters. 
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The saturation in OD450 requires further dilution of the serum in order to obtain 
meaningful titer values for the IgG antibody responses.  By performing a serial dilution of the 
collected sera and repeat the ELISA measurements (Materials and Methods), we determined that 
the IgG response elicited by p-VLPQβ has a titer between 104 and 105 (Fig. 3.5b), which occurred 
11 days after the first inoculation, and the titer increased to 105 11 days after the second 
inoculation, and thus clearly display a boosting effect.  These titer values compare favorably with 
the titer values previously reported for the same peptide but conjugated to papillomavirus-like 
particles at the same peptide dose 5.  In contrast, the IgG titer elicited by p-liposome20%-m was 
between 102 and 103 (Fig. 3.5c), which occurred 11 days after the first inoculation, and the titer 
remains between 102 and 103 after the second and third inoculation, and no boosting effect was 
observed.  These data clearly suggest that p-VLPQβ particles are much more potent than 
liposomal nanoparticles in eliciting IgG responses. 
 
Previously studies by Chackerian et al. showed that the TNF-α peptide conjugated to 
papillomavirus-like particles can actually elicit antibodies that can bind the recombinant TNF-α 
protein.  To test whether our construction of the p-VLPQβ particles can elicit the same effect, we 
thus conducted ELISA using a recombinant TNF-α protein coated on the ELISA plate.  As 
shown in Fig. 3.6, the IgG antibody elicited by both p-VLPQβ and p-liposome20%-m can bind to the 
recombinant TNF-α protein coated on ELISA plates. Similar to TNF-α peptide as coating 
material, when using TNF-α protein for ELISA, dilution factor of p-VLPQβ  serum is 1:25600 to 
reach the same level of ELISA response compared to p-liposome20%-m serum of 1:100 dilution. 
 
Why are p-VLPQβ particles much more potent than the aforementioned liposomal 
nanoparticles in eliciting IgG responses?  Among others, one difference is the size of particles, 
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while the liposomal particles we have prepared and tested have diameters around 150 nm, the p-
VLPQβ particles are about threefold smaller in their diameters.  To examine the effect of particle 
size on liposomal immunogenicity, we have thus prepared liposomal particles that are about 75 
nm in diameters (see DLS results in Fig. 3.10), again, using 20% maleimide lipids, we 
conjugated TNF-α peptides to these liposomes at a density of 9.4×104 peptides/µm2 (1721 
molecules per liposome), similar to our previous p-liposome20%-m with peptide density of 8.2×104 
peptides/µm2 (6030 molecules per liposome).  Follow the same immunization protocol and using 
the same peptide dose, we immunized C57BL/6 mice.  As shown in Fig. 3.7, these smaller 
particles elicited IgM and IgG responses, although both are very much comparable to those of 
larger liposomes.  Therefore, size of these particles did not apparently explain the huge 
difference in the immunogenicity between p-VLPQβ and p-liposomes. 
 
Because TNF-α peptide is a bona fide self antigen, even though this antigen may be 
internalized and presented by the B cells after their initial recognition by the membrane-bound B 
cell receptors, it may not find the cognate helper T cells to sustain B-cell proliferation.  This is a 
challenge especially for self-antigens, where T cells that recognize self-antigens may have been 
eliminated during their maturation 29.  In fact, the lack of boosting effect upon successive 
immunizations as we observed for the series of p-liposomes (Fig. 3.2 and Fig. 3.9) suggest the 
lack of T cell help in these IgG responses, which is in contrast to the boosting effect observed for 
p-VLPQβ in this study and also reported previously for the same peptide conjugated on the 
surface of papillomavirus-like particles3.  In fact, both the coat protein in bacteriophage Qβ and 
major capsid protein L1 in papillomavirus are foreign to mice, the inclusion of these proteins in 
the antigen presentation platforms may have thus inadvertently served this role of foreign 
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antigens for efficient recruitment of T cell help to sustain B cell activation and germinal center 
formation. 
 
To test this hypothesis, we have thus utilized two different strains of transgenic mice that 
are created in C57BL/6 background (Materials and Methods). The first line is deficient in both 
alpha beta and gamma delta T-cell receptors 19 (denoted as TCR-/-), while the second line does 
not express MHC class II molecules on the surface of splenic B cells or dendritic cells 20 
(denoted as MCII-/-), and thus both lines are deficient in T-dependent B cell activations.  We first 
immunized these two lines of transgenic mice using p-liposome20%-m, following the same 
immunization schedule and doses as we did for the wild-type C57BL/6 mice.  As shown in Fig. 
3.8a, these two lines of transgenic mice produced IgM responses that are identical within error to 
the wild-type C57BL/6 mice.  Similar IgG responses were also observed for these three lines of 
animals (Fig. 3.8b).  In particular, one-way ANOVA test conducted for these data yielded p-
values >0.05 for all three groups at Week 2, 4 and 6, suggesting that neither IgM nor IgG 
responses elicited in these animals are statistically different.  Furthermore, no boosting effect of 
IgG response was observed in either transgenic mice, consistent with the result seen in wild-type 
mice (Fig. 3.2).  These data thus confirm that the IgG response elicited by p-liposomes in wild-
type mice is a result of T-independent B cell activation. These data also showed that class-
switched antibody responses can be elicited by these p-liposomes in the absence of T cell help. 
 
We then used p-VLPQβ to immunize the two lines of transgenic mice, following the 
schedules and doses that we did previously and collected sera at designated time points to 
measure antibody responses using ELISA.  As shown in Fig. 3.8c, the IgG response from these 
animals has dropped substantially to a level that can be compared to that elicited by p-
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liposome20%-m.  This result demonstrates that the extraordinary immunogenicity of p-VLPQβ is 
almost entirely determined by the ability of these particles in recruiting T-cell help.  To the best 
our knowledge, this is the first quantitative description on the molecular origin of the 
immunogenicity of these viral-like particles.  
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3.6. Figures: 
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Figure 3.1. Characterization of liposome20%-m and liposome20%-m-TNF-α.  
(a) Tricine-SDS-PAGE and silver staining result of samples: lane 1: protein marker (natural 
polypeptide SDS-PAGE standards, Bio-Rad, # 1610326); lane 2: 0.12 pmol liposome20%-m-TNF- 
α; lane 3: 0.12 pmol liposome20%-m; lane 4: 1 4g TNF- α- peptide. (b) Dynamic light scattering 
size analysis of liposome20%-m and liposome20%-m-TNF- α. (c) Estimated number of TNF-α 
peptide per liposome is linearly correlated with maleimide percentage incorporated in liposome. 
Three independent batches of liposomes with various maleimide percentages 1.1%, 2.2%, 4.4%, 
6.6% and 20% were produced and quantitated. (d) Average number of TNF-α peptide molecules 
per liposome for four batches of liposome20%-m is estimated by Stewart lipid quantitation and 
BCA peptide quantitation. Error bars indicate the standard deviation drawn from two 
independent measurements for each batch of liposome. (e) Liposomes purified from size 
exclusion column after incubation with 50% fetal bovine serum for 1, 3, 5, and 7 days are 
measured for average size in nm by dynamic light scattering. (f) Tricine-SDS-PAGE and silver 
staining result of samples: lane 1: protein marker (polypeptide standards); lane 2-6: 0.05 pmol 
liposome20%-m-TNF- α (before FBS incubation, incubate with 50% FBS for 1 day, 3 days, 5 days 
and 7 days. (g) Estimated number of TNF-α peptide per liposome over a week of incubation with 
50% FBS calculated by the band intensity of TNF-α peptide- lipid from Fig. 3.1f.  
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Figure 3.2. Anti-TNF-α-peptide antibody production in immunized mice.  
(a-b) ELISA OD values for anti-TNF-α-peptide IgM (a) and IgG (b) antibody in mouse serum 
(1:100 dilution) after 1st immunization using PBS, liposome20%-m, TNF-α peptide (4.5 µg), and 
liposome20%-m-TNF-α peptide (4.5 µg peptide). (c-d) ELISA OD values for anti- TNF-α-peptide 
antibodies in mouse serum (1:100 dilution) during three inoculations using TNF-α peptide and 
liposome20%-m-TNF-α peptide. Blood serums were collected at week 2, week 4 and week 6, 11 
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days after each immunization. (e-f) ELISA results for anti-TNF-α-peptide antibodies in mouse 
serum (1:100 dilution) collected at week 10, week 14 and week 18. Each point presented in the 
figures represents the mean of OD450 values obtained from four mice of each group. Error bars 
represents the standard errors. Statistical difference between soluble TNF-α peptide and 
liposome-TNF-α peptide was determined by Student’s T-test (***: p-value < 0.001; **: p-value 
< 0.01; *: p-value < 0.05; NS (Not Significant): p-value > 0.05).  
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Figure 3.3. Anti-TNF-α-peptide antibody production in wild-type mice immunized with 
liposome-TNF-α of different peptide density (percentage of maleimide lipid in total lipids is 
indicated).  
 
(a-b) ELISA OD values for anti-TNF-α-peptide IgM (a) and IgG (b) antibody in mouse serum 
(1:100 dilution) after 1st immunization using liposome-TNF-α of different TNF-α surface 
densities (same dose of 4.5 µg TNF-α peptide) and soluble TNF-α peptide. (c-d) ELISA OD 
values for anti-TNF-α-peptide IgM (a) and IgG (b) antibody in mouse serum (1:100 dilution) 
after 1st immunization using liposome-TNF-α of different TNF-α surface densities with CpG 
mixed before inoculation (same dose of 4.5 µg TNF-α peptide, 20 µg CpG) and soluble TNF-α 
peptide with CpG. In all the figures above, liposome1.1%-m -TNF-α peptide was used as a 
reference to determine statistical difference by Student’s T-test.  
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Figure 3.4. Characterization of Qβ and Qβ-TNF-α. 
(a) Tricine-SDS-PAGE and silver staining result of samples: lane 1: protein marker (Thermal 
Scientific, Cat. 26614); lane 2-6: hen egg lysozyme, 14.5 kDa (800ng, 400ng, 200ng, 100ng, 
50ng); lane 7: VLPQβ (2	4g Qβ); lane 8: p-VLPQβ (4	4g Qβ). (b) Dynamic light scattering size 
analysis of VLPQβ and p-VLPQβ.  
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Figure 3.5. Anti-TNF-α-peptide antibody production in mice immunized with liposome-
TNF-α and Qβ-TNF-α.  
 
(a-b) ELISA OD values for anti-TNF-α-peptide IgM (a) and IgG (b) antibody in mouse serum 
(1:100 dilution) after three repeated inoculations using liposome-TNF-α of 20% maleimide lipid 
(4.5 µg TNF-α peptide) and Qβ-TNF-α (0.5 µg TNF-α peptide). Student’s T-test was done for 
group Qβ-TNF-α comparing to liposome-TNF-α. (c) IgG titer was determined as the dilution 
factor of serum at the point when ELISA signal was still two folds more than the background 
average OD value. Each data point represents the IgG titer result of each individual mouse from 
immunization groups. Lines represents the mean of titers.  
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Figure 3.6. Comparison of ELISA OD values of specific IgG antibody using TNF-α-peptide 
or TNF-α-protein as coating substrate.  
 
Mouse serum collected after 1st immunization of Qβ-TNF-α (0.5 µg TNF-α peptide) in 1:25600 
dilution or 1st immunization of liposome20%-m-TNF- α-peptide (4.5 µg TNF-α peptide) in 1:100 
dilution is used in ELISA with TNF-α protein (0.2 µg) coated in each well of ELISA plate.  
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Figure 3.7. Anti-TNF-α-peptide antibody production in immunized mice.  
ELISA OD values for anti- TNF-α-peptide antibodies IgM (a) and IgG (b) in mouse serum 
(1:100 dilution) during three inoculations using soluble TNF-α peptide, p-liposome20%-m (D =75 
nm) and p-liposome20%-m (D= 150 nm). Blood serums were collected at week 2, week 4 and week 
6, 11 days after each immunization.   
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Figure 3.8. Anti-TNF-α-peptide antibody production in immunized T-deficient transgenic 
mice.  
 
(a-b) Same dose (4.5 µg) of liposome-TNF-α peptide20%-m was immunized to three groups of 
mice: wild-type mice (C57BL/6J), TCR deficient mice (TCR-/-) and MHC Class II deficient mice 
(MCII-/-). ELISA OD values for anti-TNF-α-peptide antibodies IgM (a) and IgG (b) in mouse 
serum (1:100 dilution), collected at week 2, 4, 6, 10, 14 and 18. (c) ELISA OD values for anti-
TNF-α-peptide IgG antibody in mouse serum (1:100 dilution) after three repeated inoculations 
using liposome-TNF-α of 20% maleimide lipid (4.5 µg TNF-α peptide) and Qβ-TNF-α (0.5 µg 
TNF-α peptide) in WT mice, TCR-/- mice, and MCII-/- mice. Student’s T-test was done for each 
group comparing to liposome-TNF-α in WT mice. 
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Figure 3.9. Anti-TNF-α-peptide antibody production in immunized mice by liposome-TNF-
α peptide of different surface density from 6.6%-maleimide to 1.1%-maleimide.  
 
(a-b) ELISA OD values for anti-TNF-α-peptide IgM (a) and IgG (b) antibody in mouse serum 
(1:100 dilution) after 3 immunization using liposome6.6%-m-TNF-α peptide (4.5 µg peptide). (c-d) 
ELISA OD values for anti-TNF-α-peptide IgM (c) and IgG (d) antibody in mouse serum (1:100 
dilution) after 3 immunization using liposome2.2%-m-TNF-α peptide (4.5 µg peptide). (e-f) ELISA 
OD values for anti-TNF-α-peptide IgM (e) and IgG (f) antibody in mouse serum (1:100 dilution) 
after 3 immunization using liposome1.1%-m-TNF-α peptide (4.5 µg peptide). 
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Figure 3.10. Characterization of liposome20%-m and liposome20%-m-TNF-α of smaller size.  
 
Dynamic light scattering size analysis of liposome20%-m and liposome20%-m-TNF- α made with 
filter membrane of 50nm size. 
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Chapter 4 
 
Recombinant HIV-1 Gag Proteins Reversibly Assemble to Giant 
Spherical Particles Instead of Regular Virus-Like Particle 
 
 
 
 
4.1. Abstract  
 
HIV-1 Gag protein is the major structural protein for the assembly of virion particles, and 
it contains many CD4 T-cell epitopes. Although studies have been carried out using partially 
purified Gag proteins to build HIV virus-like particle, the outcomes of Gag assembly reaction 
remain controversial. Here we have developed an improved procedure for purification of several 
untagged retroviral Gag proteins from E. coli to more than 95% purity and characterized Gag 
assembly in solution. We found that HIV-1 Gag proteins can undergo nucleic acid-dependent 
aggregation with several unexpected features: (1) they form spherical particles that are as large 
as microns in diameter; (2) the size of the aggregates vary with the molar ratio between nucleic 
acids and proteins, with the average size of these particles reaching maximal at a molar ratio of 
1:2 between nucleic acids and proteins; and (3) these particles can be efficiently disassembled 
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simply upon addition of excess nucleic acids into the solution, suggesting the presence of an 
ordered assembly. Single-stranded DNA oligos that are 10 nucleotides or shorter do not support 
the formation of these particles. Furthermore, the matrix domain of the Gag protein dramatically 
facilitates the formation of these aggregates. These studies uncover a previously uncharacterized 
pathway of HIV Gag assembly in vitro and have implications for HIV-1 Gag assembly and 
pathogenesis in vivo. However, the Gag assembly is not an ideal platform for construction of 
engineered nanoparticles with tailored densities, due to the size of aggregates and inclusion of 
nucleic acids during assembly.  
 
 
4.2. Introduction 
 
Our previous work demonstrated that VLPs can efficiently activate B cells and produce 
specific class-switched antibodies through a combination of high-density antigen display and 
strong T-cell epitope. Here, we aim to build HIV VLP with high-density display of HIV 
envelope protein for vaccine development. The HIV Gag protein is the major structural protein 
that is required for the assembly of HIV virions1. Moreover, it contains many CD4+ T cell 
epitopes in HIV21,22, making it an ideal antigen carrier to elicit strong T-cell help.  
 
The Gag protein, initially synthesized as a polyprotein precursor, is composed of four 
domains: the matrix (MA, or p17), the capsid (CA, or p24), the nucleocapsid (NC, or p7), and 
the C-terminal p6 domain1, 2.  The overexpression of Gag protein alone in mammalian cells can 
produce VLPs that bud into the culture supernatant, even in the absence of cognate viral RNA 
genome, suggesting the promiscuity in the assembly process of HIV VLPs.  Indeed, in vitro 
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studies using purified Gag proteins can initiate self-assembly of VLPs even with short DNA 
oligonucleotides3.  
 
Several investigators have carried out studies of VLP assembly using purified Gag 
proteins.  Krausslich and coworkers showed that the N-terminal extension of the CA domain is 
critical for formation of spherical VLPs4.  Absence of any N-terminal extension of CA promotes 
the formation of cylindrical particles.  This result is consistent with the study by Vogt and 
coworkers, who showed that the purified recombinant protein containing the CA, NC and p6 
domains of HIV-1 could form hollow, cylindrical particles in the presence of RNA, and the 
length of the particle depended on the type of RNA added5.  Furthermore, the presence of SP1 
peptide linker C-terminal to the CA domain may also act as a conformational switch, the 
presence of which promotes spherical particle formation6.  However, the spherical particles 
formed by these purified Gag proteins, which were 90 nm in diameter, appeared to be in a 
dynamic equilibrium with aggregation, because all spheres were pelleted after centrifugation6.  In 
an independent effort, Rein and coworkers reported that small spherical particles of 25-30 nm 
diameters can be assembled by purified Gag protein in the presence of nucleic acids3.  
Furthermore, addition of a second cofactor, inositol phosphates, is required for formation of 
VLPs that resemble authentic immature HIV-1 virions7.  In contrast to these findings, Morikawa 
and coworkers showed that Gag protein can self-assemble in the absence of nucleic acids; VLPs 
that resembled authentic immature HIV-1 virions were formed at 37°C in the presence of Mg2+, 
and addition of RNA facilitated this assembly process8.  A detailed comparison of these 
assembly studies of HIV-1 Gag proteins is shown in Supplementary Table 1.  Although there are 
clear differences in the quantitative features of these particles assembled, a common feature for 
most of these particles reported is their nanoscale, with diameters ranging from 20 to 100 nm.  
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These results suggest that the assembly of Gag proteins in vitro can achieve a point of cessation, 
at which the particles no longer ‘grow’ and have a well-defined size. 
 
Here, using HIV Gag protein lacking only p6 domain (GagDp6) and Gag protein lacking 
both p6 domain and a large portion of the MA domain (GagDMADp6), we report that 
recombinant Gag proteins can form giant spherical particles (>1 µm in diameter) in the presence 
of nucleic acids, which is observed for both BH10 and NL4-3 Gag proteins.   The assembly 
process required nucleic acids and the size of particles was dependent on the molar ratio between 
nucleic acids and proteins.  Remarkably, this assembly process is reversible as addition of excess 
nucleic acids leads to the efficient disassembly of the already-formed spherical particles.  When 
a large portion of the MA domain was deleted, the average size of the particles became smaller 
but micron-sized spherical particles were still observed, suggesting that the MA domain 
facilitates but is not required for the formation of these giant spherical particles.  In contrast to 
the nanoscale particles reported previously in the literature, these studies thus reveal an 
unexpected feature of HIV Gag proteins assembly in vitro and support the presence of a dynamic 
equilibrium between particle assembly and disassembly. 
 
 
4.3. Materials and Methods 
 
DNA Constructs 
 
GagBH10 full-length and GagΔp6 BH10 DNA were amplified using HIV-1 BH10 genome 
(pBKBH10S DNA, NIH AIDS Reagent Program) as template and inserted into the prokaryotic 
expression vector pET21a by using restriction enzymes NdeI and XhoI.  The 3’ primer for 
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GagΔp6 DNA, with the following sequence 
CGTACTCGAGTTAAAAATTCCCTGGCCTTCCCT, was designed to have a stop codon at the 
end of SP2 domain so that the p6 domain is deleted upon expression. GagΔMAΔp6BH10 DNA 
was amplified by two-step PCR using pET21a- GagΔp6BH10 as template, with two pairs of 
primers designed to amplify the two portions of Gag DNA flanking the sequence that encodes 
amino acids 16-99 in the matrix domain. After overlapping PCR extension, the product was cut 
and ligated back to the same location in pET21a vector. NL4-3 GagΔp6 gene was amplified 
using pGagMBPhis plasmid as template, a generous gift from Dr. James Hurley1.  The same 
strategy in using restriction enzymes and primers was employed to amplify GagΔp6NL4-3 gene 
and insert to pET21a expression vector. Rous sarcoma virus (RSV) Gag ΔMBDΔPR DNA in 
pET3xc vector was generously provided by Dr. Volker Vogt2.  All the DNA constructs were 
sequenced and verified before protein expression and purification.  
 
Gag Protein Expression and Purification 
 
Purification of all Gag proteins were based on the published protocol from Rein et al3 but 
with important modifications.  E. coli BL21DE3 competent cells (Invitrogen) were transfected 
with expression vectors carrying the various Gag genes and cultured in LB media. Small scale 
expression was first tested by inoculating a single colony from the plates of transfection to 5mL 
LB media containing ampicillin overnight at 37°C with constant shaking at 250 rpm.  The 
overnight culture was used to inoculate 5mL fresh LB media at a ratio of 1:100, and the 
inoculum was cultured for 2-3 hours until the optical density at 600 nm (OD600nm) was at 0.6 - 
0.8.  The expression of the recombinant proteins was induced by the addition of isopropyl-beta-
D-thiogalactopyranoside (IPTG) to a final concentration of 0.5mM at 37°C.  The expression of 
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the protein was quantitated at different time points after induction by running SDS-PAGE and 
Western blotting.  
 
Large scale expression was conducted by inoculating a single colony into 50mL LB media 
and cultured overnight. 60mL of the overnight culture was then transferred to 3L fresh LB media 
and shaken until OD600 reached to 0.6-0.8.  Protein expression was induced with addition of 0.5 
mM IPTG, and the cells were grown for four more hours at 37°C. Bacteria were then harvested 
by centrifuge at 6,000 g for 7 minutes, and the pellet was stored at -80°C.  For protein 
purification, the entire procedure was conducted at 4ºC unless otherwise noted.  The cell pellet 
was first thawed and resuspended in 10-ml lysis buffer per gram of pellet (20mM Tris-HCl pH 
7.4 at 21°C, 0.75M NaCl, 10% w/v glycerol, 10mM b-mercaptoethanol) that was supplemented 
with 1mM phenylmethyl sulfonyl fluoride (PMSF), and 0.5 mg/mL egg white lysozyme.  The 
cell suspension was gently rocked for 1 hour at 4°C followed by sonication.  The cell lysate was 
centrifuged at 12,000 g for 30 minutes to clear the supernatant.  Polyethylenimine (PEI) was then 
added to the cleared cell lysate in a dropwise manner to a final concentration of 0.2% w/v, which 
was to precipitate the nucleic acids.  The supernatant from PEI treatment was then treated with 
ammonium sulfate to 233 g/L to precipitate Gag protein.  The protein pellet was resuspended 
using buffer D (20 mM Tris-HCl pH 7.4 at 21°C, 0.5M NaCl, 1 mM PMSF, 10 mM b-
mercaptoethanol), and further centrifuged at 12,000 g for 15 mins to remove any undissolved 
pellet before the next step.  
 
Cellulose phosphate resin (PC resin, fine mesh, Sigma) was treated with 0.5 M NaOH, 0.5 
M HCl, 0.2 M Tris·HCl, pH7.4, and buffer A (20 mM Tris·HCl, pH7.4 at 21°C) sequentially 
before use.  The supernatant from the re-dissolved protein solution was decanted to a 50-mL 
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polypropylene tube and 10 ml pre-treated PC resin was added.  The tube was gently rocked at 
4°C for 1 hr to allow the Gag protein binding to the PC resin.  After binding, the PC resin was 
sequentially washed with buffer A containing 0.1 M, 0.2 M, and 0.5M NaCl respectively.  The 
protein was then eluted with the same buffer containing 1M NaCl for three times, each time with 
gentle rocking for 1hr.  The protein elution was combined, and anhydrous ammonium sulfate 
was added to reach to a final concentration of 423 g/L. The protein pellet was resuspended using 
buffer D followed by centrifugation to remove any particulates. 
 
To improve the purity of Gag proteins, we added one more step of purification after the 
cation exchange using PC resin.  An HiTrap heparin HP column (1 mL, GE) were mounted onto 
Bio-Rad DuoFlow system and equilibrated in buffer A containing 0.1M NaCl.  The resuspended 
protein solution after the second ammonium sulfate precipitation was diluted with buffer A to 
lower the salt concentration to ~0.1 M, and then loaded onto the heparin column.  After loading, 
the heparin column was first washed using buffer A containing 0.5 M NaCl.  During this step, 
the majority of unwanted proteins as well as some GagΔp6 proteins were eluted.  We then 
applied buffer A containing 0.75 M NaCl to the column, during which the majority of GagΔp6 
proteins was eluted off the column.  In contrast to either GagΔp6BH10 or GagΔp6NL4-3, HIV 
GagΔp6ΔMA and RSV Gag ΔMBDΔPR were both eluted off the heparin column in buffer A 
containing 0.35 M NaCl, suggesting their weaker affinities towards polyanions.  The various Gag 
proteins eluted off the heparin column were all dialyzed into Buffer D containing 10% w/v 
glycerol, concentrated to about 5 mg/mL using protein concentrator (3kD molecular weight 
cutoff, Thermo Scientific), flash frozen and stored at -80°C.  All protein concentrations were 
determined by UV spectrometry using extinction coefficient for each protein predicted at 280 nm 
based on amino acid sequence [20] (GagΔp6 62045 M-1cm-1, GagΔp6ΔMA 47940 M-1cm-1, and 
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RSV Gag ΔMBDΔPR 49680 M-1cm-1). Throughout, 12% SDS-PAGE gel with 0.1% SDS final 
concentration was used for assessment of protein purification.  All protein samples were 
incubated with 2× Laemmlli sample buffer and heated to 95°C for 5 mins before loading onto 
gels.  Protein bands were stained with Coomassie Brilliant Blue or silver nitrate4.  The primary 
antibody used in Western blotting was mouse anti-p24 (cat#3537, NIH AIDS reagent) and the 
secondary antibody was anti-mouse alkaline phosphatase conjugated secondary antibody 
(Sigma) diluted at 1: 10,000.  
 
In vitro Assembly Reaction 
 
Protein stock solutions were thawed on ice and slowly diluted to 0.1 M NaCl with buffer F 
(20 mM Tris pH 8.0 at 21°C, 10 mM b-mercaptoethanol).  Nucleic acids were added right after 
the dilution and the solution mixed thoroughly by gentle pipetting.  The nucleic acids included in 
the study were yeast tRNA (phenylalanine specific from brewer's yeast, Sigma), 20mer-Cy3, a 
20-mer DNA (GTGGTGTCAATTACGGTAGC) with a Cy3 fluorophore conjugated to its 3’ 
end, oligo thymidylate of various lengths (IDT), and dNTP (NEB). The assembly reaction was 
incubated at room temperature for five minutes before examination by fluorescence microscopy 
or applied to grids for electron microscopy.  
 
Electron Microscopic Examination 
 
For the negative staining of the Gag assembly product, 5 µL of the assembly reaction was 
applied to carbon-coated grid (mesh size 50, Electron Microscopy Sciences), and drained with a 
filter paper after 5 minutes.  5 µL of 5% uranyl acetate was then applied to the grid and wiped off 
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with filter paper after 5 minutes.  After air-drying for 5 mins, the grids containing assembly 
samples were ready to be imaged using a JEOL 1400-plus transmission electron microscope. 
 
Flow Cytometry 
 
The flow cytometry experiments were conducted using a Miltenyi MACSQuant VYB 
digital benchtop flow cytometer.  After the assembly or disassembly reaction was initiated, at 
designated time as indicated in the figure legends, the suspensions of particles were directly 
loaded onto the flow cytometer without any additional treatment.  Both forward and side 
scattered light at 561 nm were monitored using 561/10 nm band-pass filters. 
 
 
4.4. Results and Discussion 
 
Improvements in Purification of Retroviral Gag Proteins Expressed in E. coli. 
 
Purification of recombinant HIV-1 Gag proteins that carry hexahistidine tags using Ni-
NTA affinity column have been reported in literature8, 9.  However, because hexhistidine tag 
influences the activity of nucleic acid binding proteins10,   we have started by preparing full-
length HIV-1 Gag proteins without any affinity tags from both BH10 and NL4-3 strains, the two 
different isolates of HIV that have been studied in literature for Gag assembly in vitro (Table 
4.1).  Excluding the p6 domain, the sequence identity between these two versions of Gag protein 
is 96%.  Consistent with literature report3, the full-length Gag proteins showed significant 
degradation in E. coli upon their overexpression (Fig. 4.1A).  To improve the yield of protein for 
the ease of purification, we have thus constructed overexpression plasmids for both strains in 
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which the p6 domain of Gag has been deleted (GagDP6).  The p6 domain of HIV-1 Gag protein 
is not required for particle assembly in cultured cells but is required for budding of the assembled 
particles from plasma membrane to extracellular milieu1, 11, 12.  The GagDp6 protein was reported 
to have much less degradation issues when purified from E. coli3.  Indeed, upon induction by 
addition of IPTG, the GagDp6 proteins accumulated to significant levels with less degradation 
compared to that of the full-length Gag protein (Fig. 4.1A), which provided good starting 
materials for subsequent protein purification.  Rein and coworkers have published procedures for 
purification of recombinant HIV-1 Gag proteins that do not carry any affinity tags3, 13.  The 
major purification steps in the published procedures involve fractionation through ammonium 
sulfate precipitation of the cell lysate and cation exchange column using phosphate cellulose 
resin.  We have followed these steps, but with two major modifications for the purification 
procedure described as follows. 
 
First, we added a polyethylenimine (PEI) step before ammonium sulfate precipitation of 
the cleared cell lysate.  PEI has been frequently used in the fractionation and purification of 
nucleic acids binding proteins 14, which can effectively remove nucleic acids that may present as 
a contaminant in the final purified proteins.  After we cleared the total cell lysate by 
centrifugation, we added PEI to the supernatant at a final concentration of 0.2% w/v.  Titration of 
PEI concentration in the cell lysate indicated that this concentration was sufficient to precipitate 
the bulk of nucleic acids in the cell lysate without precipitating the majority of the Gag proteins.  
After centrifugation to remove the PEI-nucleic acids pellet, the supernatant was then subjected to 
ammonium sulfate fractionation.  This PEI step worked very well.  As shown in Fig. 4.1B for the 
purification of GagDp6 from HIV isolate BH10 (GagDp6BH10), majority of the GagDp6 protein 
was retained in the supernatant after PEI precipitation (Lane 3).  Moreover, majority of GagDp6 
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protein was recovered back into the solution after precipitation using ammonium sulfate (Lane 
4). 
 
Second, we added a heparin column step after the phosphocellulose cation exchange 
column to further improve the purity of the protein.  This step is necessary because we found that 
a major impurity was still present in the eluted protein from the cation exchanger using 
phosphocellulose.  This impurity was a protein that was slightly smaller than the Gag protein.  
The Western blotting using anti-p24 monoclonal antibody revealed that the impurity also reacted 
positively with this antibody, suggesting that the impurity was a degradation product from the 
Gag protein.  Heparin column was then utilized to separate the main protein from the degraded 
product.  Gag protein of interest can be separated from the degradation product using 
concentration gradient of NaCl on the heparin column.  As a result, the purity of the final 
GagDp6 protein was over 95% as determined using SDS-PAGE and Coomassie brilliant blue 
staining (Fig. 4.1C).  Using this modified purification protocol, we were able to purify additional 
Gag proteins studied in this work, all to greater than 95% purity (Materials and Methods).  These 
include GagDp6 protein from HIV isolate NL4-3, GagDp6NL4-3, GagΔMAΔp6BH10 (Gag protein 
lacking both p6 domain and amino acid 16-99 of the matrix domain6) (Fig. 1 D,E), and a 
truncated version of the Rous sarcoma virus (RSV) Gag protein (AA85-577, RSV 
GagDMBDDPR) (Fig. 1F). 
 
In vitro Assembly Properties of HIV-1 GagΔp6 Protein 
 
To test the assembly of purified GagΔp6 BH10 protein, we diluted the protein into the 
assembly buffer to reach 0.1 M NaCl at room temperature.  Upon addition of yeast tRNA into 
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the diluted protein solution, the mixture immediately turned turbid.  In contrast, control in the 
absence of nucleic acids remained clear (Fig. 4.2A upper right).  To examine the assembly 
species formed upon addition of nucleic acids, we applied 5 µl of the turbid suspension on top of 
a clean coverslip and observed the sample under bright field in an optical microscope.  Spherical 
particles of heterogeneous size, with diameters in the range of 1-10 µm were clearly observed, as 
shown for GagΔp6BH10 in Fig. 4.2A.  To better evaluate the properties of the assembled particles, 
we designed a short DNA oligomer of 20 nucleotides labeled with a single Cy3 fluorophore at its 
3’ end (20mer-Cy3).  When this DNA oligo was added to the diluted GagΔP6 protein solution to 
initiate the assembly reaction, spherical particles of heterogeneous size, similar to those formed 
upon addition of yeast tRNA, were also observed under microscope (Fig. 4.2B).  Moreover, 
these particles were fluorescent, as shown by a fluorescence image collected through Cy3 
emission channel (Fig. 4.2C).  The fluorescence image could be overlaid very well with its bright 
field image, indicating that all the particles formed under this condition contained 20mer-Cy3 
inside (Fig. 4.2D).  Throughout, the assembly experiments were done in parallel for GagDp6 
from BH10 and NL4-3, and no significant differences in the assembly behaviors were observed 
between the two GagDp6 proteins. 
 
To examine the spherical particles formed under these conditions more closely, we next 
employed transmission electron microscopy (TEM) to image these samples.  As shown in Fig. 
4.3A, large, spherical particles with diameter ranging from 1µm to 10 µm were easily identified 
on the grid with negatively stained samples.  Interestingly, many particles showed additional 
features on their surfaces.  These surface features are highlighted in Fig. 4.3B under a higher 
magnification.  There were many needle-like thin structures about 100-200 nm in length that 
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protruded from the surface of these particles (Fig. 4.3B).  Again, GagΔp6 proteins from NL4-3 
and BH10 formed very similar particles under same assembly conditions. 
 
The fact that no spherical particles were formed by the same protein upon dilution without 
adding nucleic acids indicates that the formation of these particles required nucleic acids.  To 
gain more mechanistic information about formation of these giant spherical particles, we next 
analyzed the role of nucleic acids by systematically varying the molar ratio between nucleic 
acids and protein, and then examine the size and quantity of particles formed using fluorescence 
microscopy.  In these experiments, the 20mer-Cy3 DNA and GagDp6NL4-3 was used throughout.  
We noticed that when the molar ratio of nucleic acids to protein was below certain threshold 
(1/32), no particles were observed, clearly indicating the requirement of nucleic acids for this 
assembly process to occur.  As we further increased the amount of DNA included in the 
assembly reaction, particles started to form.  Both the average number of particles formed per 
field of view and the average particle size increased with increasing nucleic acids.  The average 
particle size reached a maximum at a molar ratio of 1:2 between the nucleic acid and the protein.  
Further increase in nucleic acids leads to less particles formed and also smaller size of spherical 
particles.  The details of these results are summarized in Table 4.2A.   
 
Limited by the stock concentration of the 20mer-Cy3 DNA, we were not able to increase 
the ratio of DNA/protein beyond 1:1 for the experiments in Table 4.2A.  However, the decrease 
in particle assembly with increasing DNA upon a defined molar ratio between the DNA and the 
protein suggests that the self-assembly process may be reversible.  To further examine this 
dependence quantitatively, we have used an oligo thymidylate, (dT)30, to repeat the experiment.  
For this set of experiments, we were able to titrate nucleic acids well above the moles of proteins 
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so to examine a wider range of nucleic acids to protein ratios.  As summarized in Table 4.2B, the 
threshold behavior of self-assembly was again observed.  The particles started to form only when 
the molar ratio of nucleic acids to protein was at 1/45 or higher.  Average size of the particles 
reached a maximum at a ratio of 1:2. As we further increased concentration of (dT)30, to more 
than two folds of GagDp6 protein, particle assembly disappeared.  No visible particles were 
formed at even higher concentrations of (dT)30 tested as examined under microscope.  This 
quantitative dependence of self-assembly on nucleic acids, where a peak in the assembly reaction 
occurs at a certain ratio of nucleic acids to protein, indicates that the self-assembly process is 
reversible. To further test this phenomenon, we first added 20mer-Cy3 to diluted GagDp6BH10 at 
a molar ratio of 1:2, where the peak of assembly occurs (Table 4.2A).  As expected, the sample 
quickly turned turbid after the addition of 20mer-Cy3.  After 5 minutes, we then added additional 
(dT)30 to a molar ratio of 8:1, and interestingly, the turbidity quickly disappeared after the 
addition of excess (dT)30. As shown by both light microscopy and fluorescence microscopy, the 
majority of large particles formed by GagDp6 and 20mer-Cy3 20mer disappeared after addition 
of (dT)30 (Fig. 4.4 A, B).  This process can also be monitored using flow cytometry.  As shown 
in Fig. 4.4C, the addition of 20mer-Cy3 to the diluted GagDp6BH10 at a molar ratio of 1:2 yielded 
a large number of heterogeneous particles, indicated by the total forward scattered light (FSC-A).  
However, upon further addition of excess (dT)30, majority of the large particles has disappeared 
(Fig. 4.4D).  As a control, GagDp6BH10 diluted in buffer F in the absence of nucleic acids did not 
produce any significant particles.  The fact that the particle assembly can be reversed by addition 
of excess nucleic acids suggests that the formation of these giant spherical particles is in a 
dynamic equilibrium with particle disassembly.  This phenomenon is very different from what 
have been reported previously in literature for the assembly of Gag proteins in vitro (Table 4.1), 
where nanoscale particles with sizes ranging from 20 to 100 nm in diameters were observed.  
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There are three major differences: (1) these particles are microns in size, and have a regular 
spherical shape, which distinguish them from irregular or amorphous aggregates reported 
previously4, 6, 15; (2) the size of the particles varies with the molar ratio between nucleic acids and 
the proteins, and (3) the particles can be disassembled upon addition of excess nucleic acids.  
Neither (2) nor (3) has been reported previously.  The peak assembly occurs at a molar ratio of 
1:2 between nucleic acids and proteins, which further suggests an ordered assembly of Gag 
proteins in the presence of nucleic acids, in contrast to the formation of unstructured protein 
aggregates. 
 
The threshold dependence of this self-assembly was also observed for yeast tRNA (Table 
4.2C).  Furthermore, the addition of dNTP instead of nucleic acids did not result in any assembly 
of the particles, despite the various concentrations we have tested.  This result suggests that a 
nucleic acid molecule of a minimum length is required to initiate the assembly reaction.  To 
further probe this potential dependence of the assembly reaction on the lengths of the nucleic 
acids molecules, we have tested oligo thymidylate of various lengths, ranging from (dT)5 to 
(dT)20.  The results are summarized in Table 4.2D, for (dT)5 and (dT)10, no particles were formed 
regardless of their concentrations used, tested at three different ratios of nucleic acids to protein 
(1:25, 1:5, and 1:1).  In contrast, particles of similar morphology could be observed for oligo 
thymidylates that are 12 nucleotides or longer.  Early studies demonstrated that the minimum 
length of nucleic acids required to stably bind to the NC domain of HIV-1 Gag protein was 5 
nucleotides16.  The fact that (dT)5 is inadequate to promote the self-assembly of GagDp6 
indicates that binding to nucleic acids by the NC domain is not sufficient to induce the assembly 
of these giant particles, additional nucleotides in the nucleic acid molecules are required.   
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In vitro Assembly of HIV-1 GagΔMAΔp6 Protein 
 
Previously, the MA domain was also reported to recognize viral genome RNA although 
the affinity of the MA domain towards nucleic acids may be weaker than that of the NC 
domain17 and this MA-RNA interaction could be abolished by the substitution of more than two 
basic residues18.  To determine the role of MA domain in the formation of these giant spherical 
particles, we next constructed a mutant for BH10 Gag protein.  In addition to the deletion of the 
p6 domain, a large portion of the MA domain, which corresponds to amino acids 16 to 99 in 
Gag, was also deleted, resulting in GagΔMAΔp6BH10.  Previously, it was reported that this large 
truncation in the MA domain changed the site of virus budding from plasma membrane to 
endoplasmic reticulum, but the morphology of resulting virions remains largely unchanged19.  In 
vitro assembly of the purified mutant Gag protein that carries this truncation in the MA domain 
and the p6 deletion yielded both regular spherical particles with external diameter of 90 nm and 
amorphous protein aggregates6.  Furthermore, these 90-nm particles did not appear to be stable, 
because all these particles were found in the pellet after centrifugation in a microcentrifuge, 
suggesting that these particles are in dynamic equilibria with protein aggregation, or 
alternatively, these particles can grow bigger with time. 
 
Using the procedures that we have developed for GagDp6, we were able to purify 
GagΔMAΔp6BH10 to more than 95% purity (Fig. 4.1E, Materials and Methods).  To induce the 
assembly of this mutant Gag protein, we followed the same procedures for GagDp6.  The stock 
protein solution was first diluted into buffer F, followed by addition of the 20mer-Cy3.  As 
shown in Fig. 4.5 A-B, GagΔMAΔp6BH10 assembled into particles that are visible under an 
optical microscope.  However, these particles are visually two to three times smaller in size 
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compared to those particles formed with GagΔp6 (Fig. 4.4 A-B). Furthermore, after 
centrifugation at 17,000 g for 5 minutes, majorities of the particles were centrifuged to form the 
pellet but leaving submicron particles in the supernatant.  These submicron particles left in the 
supernatant could be clearly visualized under fluorescence microscope, although not by the 
bright field microscope (Fig. 4.5 C-D).  In contrast, all the giant particles formed by GagΔp6 
protein were pelleted after centrifugation at 17,000 g for 5 minutes (data not shown).  These 
results suggest that the MA domain facilitates the formation of these giant particles.  Deletion of 
amino acids 16 to 99 of the MA domain does not prevent the formation of particles larger than 1 
µm in diameter.  However, the kinetics for formation of these particles is likely to be slowed 
down significantly, given the presence of submicron particles that we could clearly observe 
under a fluorescence microscope. 
 
The smaller particles formed by GagΔMAΔp6BH10, compared to GagΔp6BH10, can also be 
shown using agarose gel.  As shown in Fig. 4.6A, after addition of 20mer-Cy3 to initiate the 
assembly of both proteins, we loaded these protein-nucleic acid mixtures into a native 0.3% 
agarose gel, and the migration of different species were visualized using a Typhoon imager for 
Cy3 fluorescence.  For GagΔp6BH10, in addition to the band that corresponded to free DNA, there 
was a major band that had slowly migrated into the gel, which likely correspond to the giant 
spherical particles observed under optical microscope.  In contrast, for GagΔMAΔp6BH10, there 
was a major band that migrated further down into the gel compared to that of GagΔp6BH10, 
suggesting that these particles were indeed smaller.  Furthermore, the Cy3 bands were smearing 
across the entire gel bed, consistent with even smaller particles that can be formed by these 
proteins.  Moreover, there were also stains upstream of the sample loading well, suggesting that 
some of the protein-DNA complexes actually carried overall positive charges and thus migrated 
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towards opposite direction.  Lastly, the particles formed by GagΔp6BH10 and GagΔMAΔp6BH10 
can also be compared using flow cytometry (Fig. 4.6 B, C). The number of large particles formed 
by GagΔp6, with a FCS-A value of higher than 1k, was much more than that of GagΔMAΔp6, 
indicating that GagΔp6 formed bigger particles than GagΔMAΔp6 under the same assembly 
conditions.  As a control, GagΔMADp6BH10 diluted in buffer F in the absence of nucleic acids did 
not produce any significant particles.   
 
A major difference between current and previous studies is our use of PEI for precipitation 
of nucleic acids before fractionation and purification of various Gag proteins.  To assess whether 
the use of PEI may have caused the inadvertent formation of these giant spherical particles 
through yet unidentified mechanisms, we have purified RSV GagDMBDDPR using the very 
same procedure for HIV Gag and studied its assembly properties as a control.  The RSV 
GagDMBDDPR shares similarities to HIV-1 GagΔMAΔp6 in domain structures but very low 
primary sequence identity. This protein was purified to greater than 95% purity (Fig. 4.1F), and 
we initiated the assembly reaction in the same manner as various HIV-1 Gag proteins.  As shown 
in Fig. 4.7A, RSV GagDMBDDPR formed relatively homogenous virus-like particles as seen 
under TEM.  The diameters of these particles ranged from 70 to 80 nm in general (Fig. 4.7B), 
consistent with previous literature report25.  In contrast, those submicron particles formed by 
GagΔMAΔp6 (present in the supernatant after centrifugation) showed up as heterogeneous 
spherical particles, with size ranging from 50 nm to 1 µm in diameter (Fig. 4.7 C, D).  These 
results demonstrate that the use of PEI is not the cause for the formation of giant spherical 
particles.  Rather, the biochemical and biophysical properties of HIV-1 Gag protein give rise to 
the distinct features of the particles formed from this assembly process in vitro. 
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Our results for both GagΔp6 and GagΔMAΔp6 suggest that the self-assembly of GagΔp6 
proteins in vitro can form giant spherical particles larger than 1 µm in diameter.  These particles 
can be disassembled by addition of excess nucleic acids.  The MA domain facilitates the 
assembly of these giant particles.  None of these results have been reported previously.  
Moreover, the current results may also reconcile some observations in literature.  First, our 
results on GagΔMAΔp6 are qualitatively consistent with Gross et al.6.  They showed that the 
purified GagΔMAΔp6 proteins are capable of forming spherical particles of 90 nm in diameter, 
which are close to native HIV virions in size, but these particles are in dynamic equilibria with 
either protein aggregation or formation of even larger particles, so that they can be pelleted out 
of the solution.  Second, Campbell and Rein showed previously that GagΔp6BH10 forms spherical 
particles of 25-30 nm diameter in the presence of nucleic acid3.  As they pointed out in the paper, 
the GagΔp6BH10 solution quickly became turbid upon addition of nucleic acids, and “the turbidity 
settled to the bottom of the tube within a few hours”.  These biophysical features actually 
indicate that large particles already formed in their assembly reaction, because a suspension of 
proteinaceous particles of 25-30 nm diameter would not be visually turbid at 1 mg/ml 
concentration nor would it sediment just by gravity to the bottom of the tube within a few hours.  
Thus, current results might have been observed previously although left uncharacterized or 
quantitated.  Our results uncover a novel aspect of HIV Gag protein assembly in vitro, which is 
the dynamic equilibrium between particle assembly and disassembly.  Future studies remain 
necessary in order to identify the conditions for the formation of nanoscale particles in the range 
of 20 to 100 nm diameters, using purified HIV Gag proteins as the material.  The structural 
studies on these giant spherical particles are also necessary in order to reveal the molecular 
mechanisms that give rise to these supermolecular assemblies.
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4.6. Tables and Figures 
 
 
 
Reference HIV isolate 
Domains 
included 
Protein 
purity 
Nucleic acids 
tested in assembly Assembly condition Properties of particles 
Volker 
Vogt 
1995 
BH10 CA-NC and CA-NC-p6 ~70% Total E. Coli RNA 
Protein (1mg/mL) 
dialyzed to buffer 
0.1M NaCl, pH 8.0 at 
4°C in presence of 
RNA 
Rod-like particles of 
variable length but of 
constant 50 nm 
diameter 
Alan Rein 
1999 BH10 
MA-CA-
NC 
85%-
90% 
Total E. coli RNA, 
yeast tRNA, in 
vitro-transcribed 
RNAs, and short 
DNA oligo-
nucleotides 
Protein diluted to 
1mg/mL in 20mM 
Tris-HCl pH 8.0 with 
0.1M NaCl, 10 mM 
DTT, at room 
temperature 
Spherical particles 
25-30 nm in diameter 
Hans-
Gorge 
Krausslich 
1998 
NL4-3 
∆MA-CA 
(AA16-99 
of MA 
deleted), 
and various 
N-terminal 
extensions 
of CA 
>95%, 
and 
all >90% 
No nucleic acids 
required 
Protein diluted and 
dialyzed overnight 
against assembly 
buffer (50mM Tris-
HCl pH 8.0, 1M 
NaCl, at 4°C) 
Spherical particles 
with diameters ranged 
from 20-100 nm, 
formation with 
various efficiencies 
Hans-
Gorge 
Krausslich 
2000  
Chimera* 
∆MA-CA- 
NC 
(AA16-99 
of MA 
deleted) 
>90% 
Single-stranded 
DNA oligo-
nucleotides 
Protein dialyzed for 2 
h against 50mM 
Tris–HCl pH 8.0, 
0.1M NaCl, 1 mM 
EDTA, 1 mM DTT 
with nucleic acids at 
4°C 
Regular spherical 
particles with an 
external diameter of 
90±5 nm as well as 
amorphous protein 
aggregates 
Kouichi 
Sano 
1999 
Not 
reported 
MA-CA-
NC-6×His 95% Calf liver RNA 
protein incubated in 
the presence of 20 
mM Tris pH8.6 at 
room temperature, 
100 mM NaCl, 0.2 
mM EDTA, 1 mM 
DTT, 5 mM MgCl2 
and/or calf liver RNA 
at 37 °C for 1- 3 h 
Almost spherical, 
hollow particles 
surrounded by 
double-ring structure 
Johnson 
Mak 
2004 
NL4-3 
MA-CA-
NC-p6- 
6×His 
>95% Yeast tRNA 
Protein dialyzed 
overnight against 
buffer of 20mM Tris 
pH7.4, 150 mM 
NaCl, 10 mM DTT in 
presence of RNA at 
4°C 
Spherical particles 
with a diameter of 20 
nm 
 
 
Table 4.1. List of purified HIV-1 Gag proteins in previous publications.  
(*: Obtained from both NL4-3 (∆MA-CA speI site) and BH10 (CA speI site-NC)) 
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A. Effect of molar ratio of 20mer-Cy3 to GagΔp6NL4-3 protein on Gag self-assembly.  
 
 
20mer-Cy3 final 
concentration 
(µg/mL) 
0.83 1.83 3.67 7.33 14.67 29.17 58.33 116.7 
GagΔp6NL4-3 final 
concentration 
(mg/mL) 
1.04 
Molar ratio of 
DNA vs protein 1:128 1:64 1:32 1:16 1:8 1:4 1:2 1:1 
Average number of 
particles per field - - 79 86 109 135 119 88 
Average particle size 
(diameter in µm) - - 1.54 1.88 2.31 3.01 3.03 2.03 
 
 
 
 
B. Effect of molar ratio of (dT)30 to GagΔp6NL4-3 protein on Gag self-assembly.  
 
 
(dT)30 final 
concentration 
(µg/mL) 
1.13 2.08 4.17 8.33 16.67 53.33 108.3 215.0 430.0 858.3 1717 
Molar ratio of 
DNA vs protein 1:180 1:90 1:45 1:22 1:11 1:4 1:2 1:1 2:1 5:1 9:1 
Average number 
of particles per 
field 
- - 86 127 119 158 134 94 - - - 
Average  
particle size 
(diameter in µm) 
- - 2.65 3.1 3.48 3.5 3.92 3.44 - - - 
 
 
 
 
C. Effect of molar ratio of yeast tRNA to GagΔp6NL4-3 protein on Gag self-assembly.  
 
 
Yeast tRNA final 
concentration 
(µg/mL) 
0.005 0.01 0.021 0.042 0.083 0.167 
Molar ratio of 
DNA vs protein 1:80 1:40 1:20 1:10 1:5 1:2.5 
Average number of 
particles per field - - 82 105 105 71 
Average particle size 
(diameter in µm) - - 3.22 3.57 3.53 4.10 
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D. Self-assembly of GagΔp6NL4-3 protein with different lengths of oligo thymidylate tested at 
three different ratios of DNA to protein. 
 
 (dT)5 (dT)10 (dT)12 (dT)14 (dT)16 (dT)18 (dT)20 
1: 1 - - + + + + + 
1: 5 - - + + + + + 
1: 25 - - - - - - - 
  
The experiments were conducted with GagΔp6 NL4-3 protein; the assembled particles were observed directly under light 
microscope with a magnification of 400 times;  
+: visible particles were formed with GagΔp6NL4-3 protein  
-: no visible particles were formed with GagΔp6NL4-3 protein 
 
Table 4.2. Effects of molar ratio of nucleic acids to GagΔp6NL4-3 protein on Gag 
self-assembly outcomes.  
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Figure 4.1. SDS-polyacrylamide gel images from purification of recombinant 
retroviral Gag proteins.  
 
(A) Western blotting of the lysates from induced E. coli expressing full-length GagBH10 (Lane 
1) and GagΔp6BH10 (Lane 2). (B) Products from major steps of protein purification for HIV-1 
GagΔp6BH10. Lanes: 1: protein marker; 2: total lysate of cell pellet after 5-hour induction; 3: 
supernatant from cell lysate after 0.2% PEI treatment; 4: re-dissolution of protein pellet after 
33% ammonium phosphate precipitation; 5: elution fraction after PC resin purification; 6: final 
product after heparin column chromatography. (C–F) Purity tests for various versions of 
recombinant retroviral Gag proteins: GagΔp6BH10 (C); GagΔp6NL4-3 (D); Gag ΔMA 
Δp6BH10 (E); and RSV Gag ΔMBDΔPR (F). The amounts of protein loaded in each lane were 
30 µg, 6 µg, 3 µg, and 1.5 µg for (C), (D) and (E), corresponding to 100%, 20%, 10% and 5% 
respectively. The amounts of protein loaded in each lane for (F) were 25 µg, 2.5 µg, 1.25 µg, and 
0.5 µg, corresponding to 100%, 10%, 5% and 2% respectively.  
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Figure 4.2. In vitro assembly of HIV-1 GagΔp6BH10 protein.  
 
(A) GagΔp6BH10 formed large heterogeneous particles of diameter around 1–5 µm, when 1µg 
yeast tRNA was added to 5 µg GagΔp6BH10 diluted with buffer F. Inset: GagΔp6BH10 solution 
became turbid upon addition of yeast tRNA (right), while it remained clear in absence of yeast 
tRNA (left); (B–C) GagΔp6BH10 formed similar particles with addition of 20mer-Cy3 
compared to yeast tRNA, determined by microscope bright field figure (B) and fluorescence 
image (C). (D) Co-localization of the large particles in bright field with the red fluorescent 
particles in fluorescence image when overlapping two images of the same field from Panel C and 
D. All figures are taken under light microscope with a magnification of 400 times, and the scale 
bar indicates 10 µm.  
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Figure 4.3. Electron microscopy of HIV-1 GagΔp6NL4-3 protein self-assembly in 
presence of 20mer-Cy3.  
 
About 6µg GagΔp6NL4-3 protein stored in storage buffer (0.5M NaCl, 20nM Tris-HCl pH7.4) 
was added with four times volume of buffer F (20 mM Tris-HCl pH8.0), mixed well by gentle 
pipetting, and then added with 0.7µg 20mer-Cy3; The sample was placed at RT for 5 mins and 
then performed with negative staining. EM photos were taken at magnification of 2500 (A) and 
40000 (B), respectively. 
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Figure 4.4. Microscopy photos and flow cytometry of in vitro assembly and 
disassembly of GagΔp6BH10 protein. 
 
(A) 5 µg GagΔp6BH10 was diluted with buffer F, and then mixed with 20mer-Cy3 at a molar ratio 
of nucleic acids to protein as 1 to 2. (B) After the assembly of GagΔp6BH10 with 20mer-Cy3 
under the same conditions as in panel A, (dT)30 was added to the sample to reach a molar ratio of 
nucleic acids to protein as 8:1. After incubation at 21°C for 10 min, it was sampled and observed 
under microscope in fluorescence mode. The yellow scale bars indicate 10 µm for both panels. 
(C) Flow cytometry of the assembly formed by GagΔp6BH10incubated with 20mer-Cy3. The 
sample was prepared under same assembly conditions as in (A), and analyzed 5 min after the 
addition of nucleic acids. (D) Flow cytometry of the assembly formed by GagΔp6BH10 first 
incubated with 20mer-Cy3 and then mixed with excessive (dT)30. The sample was prepared 
under same assembly conditions as in (B). After addition of excess (dT)30, the sample was 
incubated at 21°C for 10 min before flow cytometry analysis. 
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Figure 4.5. Microscopy photos of in vitro assembly of GagΔMAΔp6BH10 protein.  
 
(A-B) GagΔMAΔp6BH10 was mixed with 20mer-Cy3 upon dilution with buffer F, placed at RT 
for 5 mins before observation under microscope at magnification of 400 times in both bright 
field (A) and fluorescence scope (B). (C-D) GagΔMAΔp6 BH10 was mixed with Cy3DNA upon 
dilution with buffer F, and the tube was centrifuged at 17,000 g for 5 mins. Supernatant from the 
mixture was sampled and observed under microscope in bright field (C) and fluorescence mode 
(D). 
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Figure 4.6. Comparison of the particles formed by GagΔp6 and GagΔMAΔp6 with 
addition of 20mer-Cy3.  
 
(A) Gel electrophoresis of assembled particles of GagΔp6 and GagΔMAΔp6 proteins. 0.3% 
Agarose gel was run in TBE buffer at voltage of 100V for 1hr at 4°C and imaged by typhoon 
imager to detect Cy3 fluorophore. Lanes: 1. Control group containing only 0.7µg 20mer-Cy3; 2. 
6µg GagΔp6NL4-3 mixed with 0.7µg 20mer-Cy3 upon dilution with buffer F; 3. 5µg 
GagΔMAΔp6BH10 mixed with 0.7µg 20mer-Cy3 upon dilution with buffer F. (B) Flow cytometry 
of the assembly formed by GagΔp6BH10 incubated with 20mer-Cy3 at the ratio of 1:2, placed at 
RT for 1hr before flow cytometry analysis. (C) Flow cytometry of the assembly formed by 
GagΔMAΔp6BH10 incubated with 20mer-Cy3 for 1hr, under same assembly conditions as Fig. 
4.5A. 
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Figure 4.7. Particles assembled by RSV GagΔMAΔp6 and HIV-1 
GagΔMAΔp6BH10 in presence of yeast tRNA. 
 
(A–B) 5.2 µg RSV GagΔMAΔp6 was mixed with 1µg yeast tRNA after dilution with buffer F, 
corresponding to a molar ratio of 1:2.5 between tRNA and protein. EM photos were taken at 
magnification of 13,000 (A) and 100,000 (B), respectively. (C–D) 5.4 µg HIV-1 
GagΔMAΔp6BH10 was mixed with 1µg yeast tRNA after dilution with buffer F, corresponding to 
a molar ratio of 1:3.3 between tRNA and protein. EM photos were taken at magnification of 
13,000 (C) and 100,000 (D), respectively. The scale bars indicate 1 µm, 100 nm, 1 µm, and 100 
nm for Panels A, B, C and D respectively.  
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Chapter 5 
Discussion of Results and Future Directions 
 
 
 
5.1. Overview of Results 
 
The low density of envelope glycoprotein on HIV surface1–3 suggest a potential 
mechanism for this virus to evade human immunity and delay the induction of neutralizing 
antibodies4. Surface antigen density has been recognized as an important factor in eliciting 
immune responses in various studies5–8, but a systematic study to investigate its impact without 
the influence of additional antigens or adjuvants is yet to be done. In this thesis work, we 
hypothesize that antigen density itself serves as an independent signal in B-cell activation, 
especially for self-antigens that are tolerated by B cells. While foreign antigens may not require 
high epitope density for B cell activation,  self-antigens may require a display of high surface 
density to elicit antibody responses9.  
 
To validate this hypothesis, a nanoparticle platform of well-controlled surface antigen 
density free of any additional immunogen or adjuvant is necessary. In Chapter 2, we designed a 
liposome nanoparticle conjugated with model proteins on the surface at a controlled density 
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through Ni-NTA-his-tag binding. Since previous literature has not established well-characterized 
methods to quantitatively measure antigen spatial densities, we developed both ensemble 
biochemical assay and single-molecule techniques to evaluate the protein density on the designed 
liposomes. The results showed that Ni-chelating liposomes can achieve well-controlled surface 
protein density, however, the protein molecules bound on liposomal surface decrease over time 
upon dilution due to the non-covalent binding between lipid Ni-NTA group and protein his-tag 
group. This apparently is not desired for in vivo application.  An alternative approach to 
conjugate proteins on liposomal surface through maleimide-cysteine reaction was utilized, 
proving to be more stable in both PBS and serum buffer condition. Therefore, maleimide-
liposome platform is selected to construct nanoparticles with various levels of surface density for 
study of B cell activation.  
 
On the maleimide-liposome platform, we conjugated TNF-α peptide at different surface 
densities, which was a self-antigen associated with rheumatoid arthritis. Current antibody 
treatment for rheumatoid arthritis achieved clinical success by neutralizing excessive TNF-" 
cytokine in patients10. Here, we showed that a high-density liposomal display of TNF-" peptide 
can elicit antibody responses specific towards TNF-" protein in wild-type mice. This is the first 
study to demonstrate that high surface density of a self-antigen can break B-cell tolerance 
without any additional T-cell epitope or adjuvant. When lowering the surface density of TNF-" 
peptide, we identified a potential density threshold between liposome1.1%-maleimide to liposome2.2%-
maleimide, below which liposomes elicited much lower antibody response in mice suggesting 
insufficient breaking of B-cell tolerance. Moreover, we discovered that high-density display of 
TNF-" peptide breaks B-cell tolerance through T-independent pathways, because T-deficient 
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transgenic mice produced same level of specific anti-TNF-" antibody as wild-type mice upon 
immunization.  
 
In order to evaluate the anti-TNF-" antibody production by liposomal display, we 
constructed Q# bacteriophage virus-like particle conjugated with the same TNF-" peptide at 
high density level for same animal immunization experiment. Q#-TNF" conjugate induced 1000 
folds higher titer of specific IgG antibody than liposome-TNF" in wild-type mice, but only 
induced similar level of IgG as liposome- TNF" in T-deficient mice, suggesting Q# VLPs can 
break B-cell tolerance of TNF" more efficiently with T-cell help. This result indicates that T 
cells are not required in recognition of high-density antigen display, but they can provide strong 
stimulation to B-cell activation and antibody production.  
 
As VLPs demonstrated a better potency in recruiting T cell help to sustain B-cell 
activation, we intend to construct VLP platforms for development of HIV vaccine candidate. 
HIV Gag protein is an ideal candidate because HIV Gag protein is shown to self-assemble to 
VLP in vitro11 and it contains multiple well-characterized human T-cell epitopes to boost 
immune responses. However, previous literature reported contradicting results in HIV Gag 
protein assembly to VLP12–15. In Chapter 4, we described our attempt in using HIV Gag protein 
to build virus-like particles. By developing an improved Gag protein purification method, we 
purified several untagged retroviral Gag proteins from E. coli to more than 95% purity. HIV-1 
Gag proteins form large spherical particles of microns in size in the presence of nucleic acids. 
More interestingly, the large particles assembled can undergo disassembly upon addition of 
excess nucleic acids, suggesting the assembly is an ordered structure. This work uncovered a 
new characteristic of HIV Gag protein in assembly in vitro that may play a role in HIV 
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intracellular assembly and pathogenesis in T cells. But for this in vitro assembly to be useful for 
production of VLPs for vaccination purpose, more work remains to be completed for the 
construction of regular virus-like particles as antigen presentation platforms. 
 
So far, we have successfully constructed liposome-based nanoparticles with controlled 
densities of antigens quantitated by both ensemble assay and single-molecule assay. Mouse 
immunization study revealed that high-density display of self-antigen by itself alone can break 
B-cell tolerance independent of T-cell help. Addition of T-cell help, although not required in B-
cell activation, greatly boosts the specific antibody response proven by Q# VLP conjugate. 
Inspired by the high immunogenicity of Q# VLP, we studied HIV Gag protein assembly process 
in vitro for construction of HIV VLP and revealed the unexpected large micron-size particle 
formation by purified HIV Gag protein. More work remains to be carried out for the correct 
assembly of HIV VLP and conjugation of antigen on the surface.  
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5.2. Future Directions 
 
In vivo and In vitro Study of B-cell Activation 
 
Immunization results in this thesis work focused on the evaluation of specific autoreactive 
antibody production elicited by liposome conjugated with antigens in mice, because antibody 
production is a key parameter in analysis of B-cell activation. To further investigate the B cell 
activation process in vivo, additional tests can be done in immunized mice: B cells isolated from 
lymph nodes and spleen can be evaluated by ELISPOT to determine the number of specific 
antibody secreting cells; lymph node B cells can be evaluated by flow cytometry to determine 
the number of activated B cells, formation of germinal centers, and the differentiation to memory 
B cells; cytokine level secreted by activated B cells can be evaluated by cytokine measurement 
assays. In summary, number of B cells activated as well as differentiation of B cells to germinal 
center or memory B cells can be evaluated to determine the immune effects of liposomes with 
different antigen densities in vivo.  
 
In vitro study using primary B cells will further elucidate the process of B cell activation 
by antigen density signal. Because the number of specific B cells for a particular antigen is 
usually at a frequency of 0.05 to 0.005% in the normal repertoire16 (even less if the antigen is 
self-antigen), it is not feasible to isolate sufficient antigen-specific B cells from wild-type mice 
for in vitro study. Here, we plan to use transgenic mice with all B cells genetically modified to 
recognize HEL (hen egg lysozyme). HEL-specific B cells will be isolated from mice and 
incubated with liposomes conjugated with HEL at different density levels. Afterwards, B cells 
will be evaluated by its surface activation signals, specific antibody production, cytokine release 
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and induced cell differentiation. Although, one potential challenge is the short life span of 
primary B cells in vitro. Our preliminary data showed that primary HEL-specific B cells start 
apoptosis process immediately after isolation and have only 20% viability in one day during in 
vitro culture, while it takes a few days for B cells to go through antigen-induced activation and 
antibody production process. Ways to increase primary B cell life span such as addition of pro-
survival stimulus can be explored17.  
 
Mechanism of B-cell Recognition of Antigen Density 
 
Our results revealed that high-density display of self-antigen TNF" can break B-cell 
tolerance and elicit autoreactive antibody production. However, the underlying mechanism of 
antigen density recognition by B cells remains to be clarified. It has been postulated that highly 
repetitive antigens can strongly crosslink B-cell receptors, forming receptor micro-clusters that 
set off a chain reaction of downstream events including initiation of calcium signaling and gene 
expression18. Upon encountering a particulate, B cells will first spread over antigen-bearing 
membrane and then contract, collecting bound antigens into a central aggregate19. In this case, a 
threshold of receptor molecule numbers is required, and low-density antigen display may fail to 
provide sufficient number of antigens for BCR binding in one encountering event. Nonetheless, 
this model fails to explain the scenario where too high of antigen density display leads to lower 
immune response20.  
 
In this thesis, we found the recognition threshold for self-antigen density is around 10,000 
– 20,000 molecules/ 4m2, which was achieved through the use of 1-2% of maleimide lipids. To 
validate this result, we plan to build liposomes with lower antigen density than 10,000 
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molecules/ 4m2 to verify their inability to elicit autoreactive antibody response. Moreover, we 
can construct liposomes with defined antigen densities between 10,000 – 20,000 molecules/ 4m2 
to determine the exact threshold for surface antigen density. However, since the antigen density 
on liposomes are only measured on average, it is inevitable to have a range of normal 
distribution in antigen density on liposomes, posing challenges to determine an accurate density 
threshold for B cell activation. Fluorescence labeling and optical tweezer technique can be used 
to solve this problem: a single B cell can be captured and tested for its activation signal upon 
contact with individual liposomes, antigen densities of which have been quantitatively measured 
through optical tweezers. This novel experiment design allows a precise control of a single cell-
liposome contact, thus offering a clear vision in B cell’s response toward different antigen 
densities.  
 
Construction of HIV VLP for Vaccine Development 
 
In the last chapter, we described our discovery of an unexpected assembly characteristic of 
HIV Gag protein forming large irregular particles instead of regular virus-like particles. Genetic 
modification to HIV Gag protein or change of assembly condition (buffer salt, pH, 
temperature…) can be further explored for efficient assembly of HIV VLP. Once HIV VLP can 
be formed, we aim to fuse antigen peptides from HIV envelope protein to Gag protein at the N-
terminus without interference to VLP assembly. These engineered VLPs will carry B-cell 
epitope from HIV surface envelope protein at a defined density as well as T-cell epitopes from 
Gag protein. The combination of both high surface density of B-cell epitope and intrinsic T-cell 
epitope may trigger efficient B-cell activation with T-cell help. As previous HIV vaccine trials 
attempt to use recombinant subunit protein for immunization, this innovative approach in the 
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development of HIV vaccine may lead to better efficacy in eliciting immune responses in a 
clinically safe manner.  
 
 
 
5.3. Concluding Remarks 
 
Surface antigen density has been shown to be an important factor in eliciting immune 
responses since the work led by Zinkernagel on B cell responses to vesicular stomatitis virus 
glycoproteins in 19937. 25 years later, we still have not completely understood the impact and 
underlying mechanisms of surface antigen density in activating B cells. One of the key issues is, 
how to quantitate and control the surface antigen density levels. In this thesis work, we 
successfully quantitated the antigen density on a synthetic liposome platform on a single-
molecule level, offering an innovative way to accurately characterize liposomal surface antigen 
densities. Although the antigen density can be well controlled through lipid formulation, the 
distribution of antigen densities on liposomes tends to be wider than expected. Moreover, the 
fluidity of liposome membrane causes constant movement of surface antigen molecules, possibly 
leading to higher antigen density upon encountering B cell membrane. In comparison, virus-like 
particles assembled from fixed number of protein molecules may have a narrower distribution in 
their surface antigen densities, and the configuration of surface molecules is also rigid, perhaps 
making it more advantageous in building a well-controlled antigen presenting platform. 
 
Another important question we have answered is, whether antigen density it alone can be 
an activation signal. Our results proved that liposomes of high-density antigen display without 
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any additional T cell epitope or adjuvant can effectively activate B cells in vivo. Liposome 
system free of other proteins and nucleic acids served as a simple, pure and non-immunogenic 
platform to showcase the effects of different antigen densities. Meanwhile, our results using Q# 
VLP conjugate demonstrated the strong boosting effects of T-cell epitope, and addition of CpG 
demonstrated the boosting effect of TLR ligands. Further studies on how T-cell help and TLR 
signaling facilitated B cell activation, particularly for high-density antigen display on 
nanoparticles, will be carried out to complete our current understanding in the process of antigen 
density recognition. 
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